Training Program Directors’ Breakfast (Training Program Directors and Associate Training Program Directors Only)

**Session Type:** Special Session  
**Time:** 7:30 AM - 9:00 AM  
**Location:** S404

- Welcome and Introductions, ASCO Projects and Resources  
  *James M. Ford, MD (Chair)*
- Workforce Advisory Group and Fellow Engagement in QOPI  
  *Michael P. Kosty, MD, FACP*
- ASCO MedOnc In-Training Exam Statistics  
  *Gregory A. Masters, MD*
- ASCO University: New Site and Platform Designs and EEOF Report  
  *Lisa Johnson, MHS, MT(ASCP)SC*
- New 2012 ACGME Program Requirements and Open Discussion  
  *Thomas H. Davis, MD*

Adjuvant Therapy for Older Patients

**Session Type:** Education Session  
**Time:** 8:00 AM - 9:15 AM  
**Location:** E Arie Crown Theater

- Adjuvant Treatment in Older Patients with Breast Cancer  
  *Cynthia Owusu, MD, MS*
- Adjuvant Chemotherapy for Older Patients with Colon Cancer  
  *Nadine Jackson McCleary, MD*
- Adjuvant Treatment in Older Patients with Lung Cancer  
  *Jeffrey Crawford, MD*
- Decision Making for Adjuvant Treatment in Older Patients: Treat or Not Treat  
  *Arti Hurria, MD (Chair)*

Biologic Principles of Targeted Combination Therapy

**Session Type:** Education Session  
**Time:** 8:00 AM - 9:15 AM  
**Location:** S100bc

- The Opportunities and Pitfalls of Targeted Therapeutic Combinations in Solid Tumors  
  *Johann Sebastian De Bono, MB, ChB, FRCP, MSc, PhD (Chair)*
- Combination Therapies for Melanoma: Insights from Preclinical and Clinical Trials  
  *Antoni Ribas, MD*
- Developing Phase I Trials of Targeted Therapeutic Combinations  
  *Geoffrey Shapiro, MD, PhD*

Curative-Intent Treatment of Colorectal Cancer Metastases

**Session Type:** Education Session  
**Time:** 8:00 AM - 9:15 AM  
**Location:** E Hall D2

- The Medical Oncologist View of Curative-Intent Liver Therapy  
  *Leonard Saltz, MD (Chair)*
- Role of Interventional Radiologist in Treating Liver Metastases for Colorectal Cancer  
  *Stephen Barnett Solomon, MD*
• Who, What, and When To Do Liver Surgery in Colorectal Cancer
  Steven A. Curley, MD

Session Title: Targeted Therapies in Targeted or Untargeted Sarcomas
Session Type: Education Session
  Time: 8:00 AM - 9:15 AM
  Location: S406
• Making Sense of SUCCEED and PALETTE in Unselected Sarcomas of Soft Tissue
  Richard F. Riedel, MD (Chair)
• From Bench to Clinic: Inflammatory Myofibroblastic Tumor, Ewing, Perivascular Epithelioid Cell Neoplasm, and Chondrosarcomas
  Andrew J. Wagner, MD, PhD
• From Clinic to Bench: Antiangiogenics and IGF1R in Sarcomas
  Robert G. Maki, MD, PhD

Session Title: Stage I Testicular Cancer Management Options: Surgery, Radiation, Chemotherapy, or Surveillance - Ticketed Session
Session Type: Meet the Professor Session
  Time: 8:00 AM - 9:15 AM
  Location: E451a
• Surgery, Radiation, Chemotherapy, or Surveillance in Patients With Stage I Testicular Cancer: Weighing the Options
  George J. Bosl, MD
• Adjuvant Chemotherapy for Stage I Testicular Cancer
  Carsten Bokemeyer, MD

Session Title: Myelodysplastic Syndrome, Myeloproliferative Neoplasms, and Bone Marrow Failure States - Ticketed Session
Session Type: Clinical Problems in Oncology Session
  Time: 8:00 AM - 9:15 AM
  Location: E451b
• Myelodysplastic Syndromes among Clonal Myeloid Disorders: Unique Treatments
  Mikkael A. Sekeres, MD, MS
• Chronic Myelogenous Leukemia: Entering the Second Decade of Tyrosine-Kinase Inhibitors
  Jane Apperley, MD (Chair)
• Bone Marrow Failure States
  Blanche P Alter, MD, MPH

Session Title: Highlights of the Day I Including Clinical Trials Participation Awards
Session Type: Highlights of the Day
  Time: 8:00 AM - 9:30 AM
  Location: E Hall D1
• Chair
  Harold J. Burstein, MD, PhD
• Gastrointestinal (Noncolorectal) Cancer
  Colin D. Weekes, MD, PhD
• Gynecologic Cancer
  Ronald J. Buckanovich, MD
• Lymphoma
  Ranjana Advani, MD
• Pediatric Oncology
  Clare Twist, MD
• Genitourinary (Nonprostate) Cancer
  Maria De Santis, MD

Session Title: Optimizing Delivery of High-Quality Cancer Care
Session Type: Clinical Science Symposium
  Time: 8:00 AM - 9:30 AM
  Location: S504

• Co-Chair
  Jennifer J. Griggs, MD, MPH
• Co-Chair
  Winson Y. Cheung, MD, MPH

• Patterns of decision making about cancer clinical trial participation among the online cancer treatment community: A collaboration between SWOG and NexCura. (Abstract #CRA6009)
  Joseph M Unger

• Do insurance status and neighborhood characteristics explain why minorities underutilize NCI cancer centers? (Abstract #6010)
  Lyen C. Huang

• Discussion
  Terrance Lynn Albrecht, PhD

• Insurance status and cancer disparities in adolescents and young adults age 15 to 39: National Cancer Data Base, 1998-2003. (Abstract #6011)
  Anthony Robbins

• Racial differences in the impact of financial hardship on the intensity of end-of-life cancer care. (Abstract #6012)
  Reginald D Tucker-Seeley

• Discussion
  Blase N. Polite, MD, MPH

Session Title: Breast Cancer - HER2/ER
Session Type: Oral Abstract Session
  Time: 8:00 AM - 11:00 AM
  Location: N Hall B1

• Co-Chair
  Anna Maria Storniolo, MD
• Co-Chair
  Anne F. Schott, MD

• Impact of concurrent (CON) and sequential (SEQ) radiotherapy (RT) with adjuvant aromatase inhibitors (AI) in early-stage breast cancer (EBC): NCIC CTG MA.27. (Abstract #500)
  Abdullah Khalaf Altwairgi

• Discussion
  Lori J. Pierce, MD

• Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. (Abstract #501)
  Lois E. Shepherd

• Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): The influence of menopausal status and age on treatment effects. (Abstract #502)
  Helen Marshall

• Discussion
  Gabriel N. Hortobagyi, MD

• Whole genome sequencing to characterize luminal-type breast cancer. (Abstract #503)
  Matthew James Ellis
• Intrinsic subtype and its clinical significance in early node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy. (Abstract #504)

  Ewan K.A Millar

• 13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer. (Abstract #505)

  Renata Duchnowska

• Discussion
  Martine J. Piccart-Gebhart, MD, PhD

• Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. (Abstract #LBA506)

  Andre Robidoux

• Discussion
  Gunter Von Minckwitz, MD, PhD

Session Title: Head and Neck Cancer
Session Type: Oral Abstract Session
Time: 8:00 AM - 11:00 AM
Location: E354b

• Chair
  A. Dimitrios Colevas, MD

• DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5500)

  Ezra E. W. Cohen

• The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). (Abstract #5501)

  Robert I. Haddad

• Discussion
  Jan Baptist Vermorken, MD, PhD

• A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). (Abstract #5502)

  Jordi Giralt

• Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5503)

  Renato Martins

• Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial. (Abstract #5504^)

  Jan Stoehlmacher-Williams

• Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03. (Abstract #5505)

  Joel Guigay

• Discussion
  Paul M. Harari, MD

• PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers. (Abstract #5506)

  Sofia Lyford-Pike

Yi Li

Discussion

Robert L. Ferris, MD, PhD

Session Title: Myeloma
Session Type: Oral Abstract Session
Time: 8:00 AM - 11:00 AM
Location: E354a

Chair

Rafat Abonour, MD

Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma. (Abstract #8009)

Brigitte Kolb

A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide, and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. (Abstract #8010)

Joseph Mikhael

Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX). (Abstract #8011)

Andrzej J. Jakubowiak

Discussion

Robert Z. Orlowski, MD, PhD

PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. (Abstract #8012)

Melissa Alsina

Phase I trial of obatoclax mesylate in combination with bortezomib for treatment of relapsed multiple myeloma. (Abstract #8013)

A. Keith Stewart

Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol. (Abstract #8014)

Philippe Rodon

Discussion

Asher Alban Akmal Chanan-Khan, MD

Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results. (Abstract #8015)

Gareth J Morgan

Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT). (Abstract #8016)

Ravi Vij

Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM). (Abstract #8017)

Sagar Lonial

Discussion

Irene M. Ghobrial, MD

Session Title: Central Nervous System Tumors
Session Type: Oral Abstract Session  
Time: 8:00 AM - 11:15 AM  
Location: S100a  

- Co-Chair  
  Louis B. Nabors, MD  

- Co-Chair  
  Eric L. Chang, MD  

- MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial. (Abstract #2000)  
  Wolfgang Wick  

- A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multiplatform biomarker profiles. (Abstract #2001)  
  Arnab Chakravarti  

- The NFκB pathway as a key mediator of the glioblastoma mesenchymal subtype in glioblastoma stem cells and human tumors. (Abstract #2002)  
  Brian D. Vaillant  

- Discussion  
  Elizabeth A. Maher, MD, PhD  

- Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM). (Abstract #2003)  
  Mark R. Gilbert  

- Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials. (Abstract #2004)  
  Wenting Wu  

- Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. (Abstract #2005)  
  Brian Michael Alexander  

- Discussion  
  Donald A. Berry, PhD  

- Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome. (Abstract #2006)  
  Richard Charles Curry  

- Elderly patients with primary CNS lymphoma: Results from the G-PCNSL-5G-1 trial. (Abstract #2007)  
  Patrick Roth  

- Rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) followed by consolidation high-dose chemotherapy (HDC) and autologous stem-cell transplant (ASCT) for newly diagnosed primary CNS lymphoma (PCNSL). (Abstract #2008)  
  Antonio Marcilio Padula Omuro  

- Discussion  
  Andres J. Ferreri, MD  

- Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study. (Abstract #2008b)  
  J. Gregory Cairncross
Discussion Time: 11:30 AM - 12:30 PM
Discussion Location: S100a

- Co-Chair
  Dean E. Brenner, MD
- Co-Chair
  Larissa A. Korde, MD

**Brd. 1**
- Routine universal screening for Lynch syndrome in colorectal cancer patients in the community setting. (Abstract #1512)
  Jeffrey M. Goldberg

**Brd. 2**
- An alternative approach to identify women at risk for colorectal cancer. (Abstract #1513)
  Amanda S. Bruegl

**Brd. 3**
- Use of clinical history (CH) for Lynch syndrome (LS) risk assessment: An economic decision analysis. (Abstract #1514)
  Sarmad Sadeghi

**Brd. 4**
- Next-generation sequencing to identify candidate gene for hereditary mixed polyposis syndrome. (Abstract #1515)
  Michele Caroline Gornick

**Brd. 5**
- PTEN germline mutations in patients first tested for other hereditary cancer syndromes: Would use of risk assessment tools have reduced health care costs? (Abstract #1516)
  Jessica Mester

**Discussion**
- Jeffrey N. Weitzel, MD

**Brd. 7**
- Risk-reducing salpingo-oophorectomy and prophylactic mastectomy among BRCA mutation “previvors.” (Abstract #1518)
  Laura L. Holman

**Brd. 8**
- Pathologic findings at risk-reducing salpingo-oophorectomy among women at increased ovarian cancer risk: Results from GOG-199. (Abstract #1519)
  Phuong L. Mai

**Brd. 9**
- A multi-institution study of the accuracy of BRCAPRO in predicting BRCA1/BRCA2 mutations in women with ovarian cancer. (Abstract #1520)
  Molly S Daniels

**Brd. 10**
- Alcohol and breast cancer risk in postmenopausal women: The PLCO experience. (Abstract #1521)
  Roni Falk

**Brd. 11**
- Contribution of TP53 p.R337H mutation to breast cancer prevalence in Brazil. (Abstract #1522)
  Patricia Ashton-Prolla

**Brd. 12**
- Genetic polymorphisms of the OPG gene associated with breast cancer. (Abstract #1523)
  Gunter Assmann
• Discussion
  Allison W. Kurian, MD, MSc
Brd. 13
• Breast cancer intrinsic subtypes by PAM50 in older women. (Abstract #1524)
  Emily Oldham Jenkins
Brd. 14
• Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial
decision making for chemotherapy in early-stage breast cancer. (Abstract #1525)
  Shelby D. Reed
Brd. 15
• Racial disparities in treatment patterns and clinical outcomes in patients (pts) with HER2+
metastatic breast cancer (MBC). (Abstract #1526)
  Adam Brufsky
Brd. 16
• Associations between allergies and risk of hematologic malignancies: Results from the
Vitamins and Lifestyle (VITAL) cohort study. (Abstract #1527)
  Mazyar Shadman
• Discussion
  Dawn L. Hershman, MD, MS
Brd. 18
• Outcomes from an electronic medical record (EMR)-based standardized tobacco assessment
and cessation program in a NCI-designated comprehensive cancer center. (Abstract #1529)
  Graham Walter Warren
Brd. 19
• Potential risk of asbestos exposure among Japanese general population: Japanese general
screening study for asbestos-related diseases (JGSARD). (Abstract #1530)
  Nobuhiko Seki
Brd. 20
• Never-smoking women with lung cancer from the Spanish WORLD07 database. (Abstract #
1531)
  Dolores Isla
Brd. 22
• Clinical characteristics and natural history of patients with squamous cell lung carcinoma with
FGFR1 amplification. (Abstract #1533)
  Marc Christiaan Allardt Bos
Brd. 23
• Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with
advanced lung adenocarcinoma (PIONEER). (Abstract #1534)
  Pan-Chyr Yang
Brd. 24
• Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-
treated stage-IV non-small cell lung cancer (NSCLC). (Abstract #1535)
  Abul Kalam Azad
Brd. 25
• Second malignant neoplasms (SMN) among 18,627 testicular cancer survivors (TCS) after
chemotherapy (CHEM) or surgery (SURG). (Abstract #1536)
  Chunkit Fung
• Discussion
  Charles M. Rudin, MD, PhD
Session Title: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Session Type: Poster Discussion Session

Display Time: 8:00 AM - 12:00 PM

Display Location: E450a

Discussion Time: 11:30 AM - 12:30 PM

Discussion Location: E Hall D2

• Co-Chair
  Janessa J. Laskin, MD
• Co-Chair
  Bilal Piperdi, MD

Brd. 1
• Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): Outcomes of a propensity score-matched analysis. (Abstract #7009)
  Suresh Senan

Brd. 2
• The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). (Abstract #7010)
  Joel W. Neal

Brd. 3
• Pilot SCAT trial: Spanish customized adjuvant chemotherapy (CT) based on BRCA1 mRNA expression levels (I) in resected stage II-IIIA non-small cell lung cancer (NSCLC) patients (p). (Abstract #7011)
  Jose Miguel Sanchez

Brd. 4
• Feasibility trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CDDP) followed by maintenance chemotherapy of S-1 in completely resected non-small cell lung cancer (NSCLC): Thoracic Oncology Research Group (TORG) 0809. (Abstract #7012)
  Seiji Niho

Brd. 5
• MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy. (Abstract #7013)
  Jean-Louis Pujol

Brd. 6
• Quantitating pathologic response to neoadjuvant chemotherapy in KRAS-mutated versus nonmutated lung cancers. (Abstract #7014)
  Jamie E. Chaft

• Discussion
  Steven M. Keller, MD

Brd. 9
• Updated results of a phase III trial comparing standard thoracic radiotherapy (RT) with or without concurrent daily low-dose carboplatin in elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC): JCOG0301. (Abstract #7017)
  Hiroaki Okamoto

Brd. 10
• SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/radiotherapy (RT) followed by consolidation docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC). (Abstract #7018)
  Antoinette J. Wozniak
• A randomized, multicenter phase II study investigating additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Reporting on the efficacy. (Abstract #7019)
  *Michel M van den Heuvel*

• Favorable outcomes with chemoradiation and surgery for locally advanced non-small cell lung cancer: The BC Cancer Agency Vancouver experience. (Abstract #7020)
  *Wen Wen Shan*

• Discussion
  *William J. Petty, MD*

• Comparison between diameters of the whole nodule and solid area and the proportion of GGO in the tumor shadow on HRCT in predicting less-invasive lung cancer and recurrence after complete resection in patients with clinical N0 NSCLC. (Abstract #7021)
  *Haruhisa Matsuguma*

• Vorinostat (V) intratumoral levels and biomarker response in a window of opportunity trial in patients with resectable aerodigestive tract cancer. (Abstract #7022)
  *Konstantin H. Dragnev*

• Use of a proliferation-based mRNA signature to predict outcome in early-stage non-small cell lung adenocarcinoma. (Abstract #7023)
  *Carmen Behrens*

• Predictors of survival after resections of synchronous lung cancers located in multiple lobes: A multi-institutional pooled analysis. (Abstract #7024)
  *Tawee Tanvetyanon*

• Prognostic impact of the number of examined lymph nodes (LN) in resected node negative (pNo) non-small cell lung cancer (NSCLC). (Abstract #7025)
  *Obiageli Uchenna Ogbata*

• The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patients. (Abstract #7026)
  *MARK Krasnik*

• Discussion
  *David Harpole, Jr., MD*

• Randomized phase II trial comparing two schedules of thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCCL). (Abstract #7027)
  *Bjørn Henning Grønberg*

  *Kaoru Kubota*
• Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM). (Abstract #7029)
  Lee M. Krug

• Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial. (Abstract #7030)
  Raffit Hassan

• Comparison of prognostic impact between metabolic and radiologic response after induction chemotherapy for resectable malignant pleural mesothelioma: A multicenter study. (Abstract #7031)
  Yasuhiro Tsutani

• Next-generation sequencing of thymic malignancies. (Abstract #7032)
  Milan Radovich

• Phase II study of cixutumumab (IMC-A12) in thymic malignancies. (Abstract #7033)
  Arun Rajan

• Discussion
  Julie R. Brahmer, MD

---

**Session Title:** Pediatric Oncology  
**Session Type:** Poster Discussion Session  
**Display Time:** 8:00 AM - 12:00 PM  
**Display Location:** S405  
**Discussion Time:** 11:30 AM - 12:30 PM  
**Discussion Location:** S504

• Co-Chair  
  Susan Lerner Cohn, MD

• Co-Chair  
  Sharon H Savage, MD

**Brd. 1**
• Effect of radiation on outcome of types II and III PPB: A report from the International Pleuropulmonary Blastoma Registry. (Abstract #9521)  
  Gretchen M Williams

**Brd. 2**
• Outcome of 116 cases of pleuropulmonary blastoma type I and type Ir (regressed): A report from the International PPB Registry (IPPBR). (Abstract #9522)  
  Yoav H. Messinger

**Brd. 3**
• Increase in the incidence of differentiated thyroid carcinoma in children, adolescents and young adults (AYA): A population-based study. (Abstract #9523)  
  Lucas B. Vergamini

**Brd. 4**
• Treatment of pediatric stage IA lymphocyte-predominant Hodgkin lymphoma with surgical resection alone: A report from the Children's Oncology Group. (Abstract #9524)  
  Burton Appel
• Family history of cancer and clinical outcome in pediatric oncology. (Abstract #9525)
  
  Joshua David Schiffman

• Discussion
  
  Rochelle Bagatell, MD

Br. 6

• Dietary intake and metabolic syndrome in adult survivors of childhood cancer. (Abstract #9526)
  
  Webb A Smith

Br. 7

• Association of bone mineral density with incidental renal stone in long-term survivors of childhood acute lymphoblastic leukemia. (Abstract #9527)
  
  Prasad Laxman Gawade

Br. 8

• Renal carcinoma following therapy for cancer in childhood: A report from the Childhood Cancer Survivor Study. (Abstract #9528)
  
  Carmen Louise Wilson

Br. 9

• A longitudinal study of anthracycline cardiotoxicity in pediatric Ewing sarcoma. (Abstract #9529)
  
  Tanya Renae Brown

Br. 10

• Effect of dexrazoxane on impaired mitochondrial structure and function in doxorubicin-treated childhood ALL survivors. (Abstract #9530)
  
  Steven E. Lipshultz

Br. 11

• Tumor location and neurocognitive impairment in adult survivors of pediatric brain tumors: A report from the St. Jude Lifetime Cohort (SJLIFE). (Abstract #9531)
  
  Tara M. Brinkman

Br. 12

• Parent-reported cognition and its clinical applications in pediatric oncology. (Abstract #9532)
  
  Jin-Shei Lai

• Discussion
  
  Kevin C. Oeffinger, MD

Br. 13

• Outcome analysis of non-high-risk neuroblastoma patients enrolled on Children’s Oncology Group trials P9641 and A3961. (Abstract #9533)
  
  Holly Jane Meany

Br. 14

• Genome-based outcome prediction in MYCN nonamplified high-risk neuroblastoma. (Abstract #9534)
  
  Andres Eduardo Morales La Madrid

Br. 15

• Relationship of fusion protein status and outcome for children with intermediate-risk rhabdomyosarcoma: A Children’s Oncology Group report. (Abstract #9535)
  
  Stephen Skapek
• Association of chromosome complexity with age and metastasis in synovial sarcomas: Validation of expression and genomic prognostic signatures. (Abstract #9536)
  
  Fred Chibon

• Evaluation of local control strategies in patients with localized Ewing sarcoma of bone: A report from the Children’s Oncology Group. (Abstract #9537)
  
  Steven G. DuBois

• Conservative treatment of intraocular retinoblastoma: A prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy. (Abstract #9538)
  
  Isabelle Aerts

• Carboplatin (CBP) versus cisplatin (CP) within prognostic groups in pediatric extracranial malignant germ cell tumors (MGCTs). (Abstract #9539)
  
  Juliet Hale

• Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study. (Abstract #9540)
  
  Rochelle Bagatell

• A phase I trial of IMC A12 and temsirolimus in children with refractory solid tumors: A Children’s Oncology Group study. (Abstract #9541)
  
  Maryam Fouladi

• A phase I trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refractory solid tumours. (Abstract #9542)
  
  Darren R Hargrave

• Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4. (Abstract #9543)
  
  Anne L. Angiolillo

• The application of radiotherapy to the pediatric preclinical testing program: Results of a pilot study. (Abstract #9544)
  
  Christopher E. Pelloski

• Ipilimumab: First results of a phase I trial in pediatric patients with advanced solid tumors. (Abstract #9545)
  
  Melinda S. Merchant

• Discussion
  
  Peter C. Adamson, MD

---

**Session Title:** Genitourinary Cancer

**Session Type:** General Poster Session

**Time:** 8:00 AM - 12:00 PM

**Location:** S Hall A2
Brd. 1A
• Intravesical sequential BCG and electromotive mitomycin versus BCG alone in high risk non-muscle invasive bladder cancer. (Abstract #4572)
  
  Savino Mauro Di Stasi

Brd. 1B
• Expression of MET and HGF in bladder cancer tumorigenesis and invasion. (Abstract #4573)
  
  Randy F. Sweis

Brd. 1C
• Results of a phase II study of pralatrexate in patients with advanced/metastatic relapsed transitional cell carcinoma of the urinary bladder. (Abstract #4574)
  
  Yohann Loriot

Brd. 1D
• Defining a nine-biomarker panel for predicting bladder cancer outcome in combination with smoking intensity: A report from the Los Angeles Cancer Surveillance Program. (Abstract #4575)
  
  Anirban Pradip Mitra

Brd. 1E
• The impact of preoperative ASA score and serum albumin on early complication and survival rate of patients undergoing radical cystectomy for bladder cancer. (Abstract #4576)
  
  Hooman Djaladat

Brd. 1F
• FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors. (Abstract #4577)
  
  Jonathan E. Rosenberg

Brd. 1G
• A pre-cystectomy decision model to predict pathologic upstaging and oncologic outcomes in clinical stage T2 bladder cancer. (Abstract #4578)
  
  Siamak Daneshmand

Brd. 2A
• BRCA1, RAP80, and AEG-1 mRNA expression in resectable muscle-invasive bladder cancer (MIBC) patients (p) treated with neoadjuvant cisplatin-based chemotherapy. (Abstract #4579)
  
  Albert Font Pous

Brd. 2B
• Multidimensional investigation of HER2 in advanced urothelial carcinoma (UC). (Abstract #4580)
  
  Rachel S. Park

Brd. 2C
• Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC). (Abstract #4581^)
  
  Arjun Vasant Balar

Brd. 2D
• PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target? (Abstract #4582)
  
  Joaquim Bellmunt Molins

Brd. 2E
• Multicenter randomized phase II trial of gemcitabine-platinum with or without trastuzumab (T) in advanced/metastatic urothelial carcinoma (a/mUC) with HER2 overexpression. (Abstract #4583)
  
  Stephane Oudard
• PIK3CA gene alterations in bladder cancer: Analysis of correlative series of transurethral resection (TUR)—Correlation with grade histology and tumor size. (Abstract #4584)
  
  Daniel E. Castellano

• External validation of somatic copy number alteration (SCNA) at chromosome 1q23.3 in advanced urothelial carcinoma (UC). (Abstract #4585)

  Markus Riester

• A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. (Abstract #4586)

  Noah M. Hahn

• Long-term progression-free survival (PFS) and overall survival (OS) to pemetrexed (P) as single agent in metastatic urothelial carcinoma (MUC): A Spanish Oncology Genitourinary Group (SOGUG) systematic review. (Abstract #4587)

  J. M. Cervera Grau

• Clinical validation of the 7th AJCC-TNM nodal staging system in lymph node-positive patients undergoing radical cystectomy. (Abstract #4588)

  Eila C. Skinner

• Mortality from other malignancies in bladder cancer survivors. (Abstract #4589)

  Hamed Ahmadi

• Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09). (Abstract #4590)

  Guenter Niegisch

• Novel oncogenic function of ATDC in bladder cancer. (Abstract #4591)

  Phillip Lee Palmbos

• External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. (Abstract #4592)

  Andrea Borghese Apolo

• Activity of intravesical CG0070 in Rb-inactive superficial bladder cancer after BCG failure: Updated results of a phase I/II trial. (Abstract #4593)

  Terence W. Friedlander

• Utilization and predictors of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the Veterans Health Administration. (Abstract #4594)

  Gurdarshan Singh Sandhu

• Late gastrointestinal (GI) complications in patients with stage I-II testicular seminoma treated with radiotherapy (RT). (Abstract #4595)

  Christopher Leigh Hallemeier
• Interim results of phase II trial of the cyclin-dependent kinase 4/6 inhibitor PD-0332991 in refractory retinoblastoma protein positive germ cell tumors. (Abstract #4596)
  
  David J. Vaughn

• Bone metastases in patients with relapsed/refractory germ cell tumors (GCT) undergoing first salvage chemotherapy: A retrospective analysis of a large international database. (Abstract #4597)
  
  Karin Oechsle

• Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Results with PNET-based chemotherapy. (Abstract #4598)
  
  Amit Jain

• Clinical relevance of specialist pathologic testicular tumor review. (Abstract #4599)
  
  David N. Church

• Quality of life and late toxicities in germ-cell cancer patients after high-dose chemotherapy. (Abstract #4600)
  
  Thomas Wuendisch

• Residual tumor resections (RTR) in patients with germ cell tumors (GCT) after salvage chemotherapy. (Abstract #4601)
  
  Christian Winter

• Can abdominal ultrasound replace CT scanning in long-term follow-up of male patients with germ cell tumor? (Abstract #4602)
  
  Arthur Gerl

• Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors. (Abstract #4603)
  
  Thomas E. Hutson

• Genetic determinants of long-term response to rapalog therapy in advanced renal cell carcinoma (RCC). (Abstract #4604)
  
  Martin Henner Voss

• Correlation of chromosome (Chr) 14 loss and 5q gain with outcomes of pazopanib treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC). (Abstract #4605)
  
  Gary R. Hudes

• Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study. (Abstract #4606)
  
  Michael B. Atkins

• Evolving trends in non-clear cell renal cell cancer (RCC) epidemiology: A large registry analysis of 4,483 patients. (Abstract #4607)
  
  Ashok P. Pai
Selecting renal cell carcinoma therapy: Ranking of patient perspective on toxicities. (Abstract #4608)

Michael K.K. Wong

Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC). (Abstract #4609)

Housam Haddad

Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies. (Abstract #4610)

Philip S Hall

Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC). (Abstract #4611)

Axel Bex

Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review. (Abstract #4612)

Hongbo Yang

Xp11.2 translocations in adult renal cell carcinomas with clear cell and papillary features. (Abstract #4613)

Susanne M. Chan

A phase I study of pazopanib (P) combined with bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors. (Abstract #4614)

Sylvie Negrier

Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience. (Abstract #4615)

Marc Ryan Matrana

Circulating mir-21 and mir-378 are predictive of progression-free survival (PFS) in patients treated with everolimus in metastatic renal cell cancer (mRCC). (Abstract #4617)

James Lin Chen

Evaluation with DCE-US of antiangiogenic treatments in 539 patients allowing the selection of one surrogate marker correlated to overall survival. (Abstract #4618)

Nathalie Lassau

Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC). (Abstract #4619)

Avivit Peer
• Prospective exploratory analysis of the association between genetic polymorphisms and sunitinib toxicity and efficacy in metastatic renal-cell carcinoma. (Abstract #4620)

  Carlos Alberto Farfan

• Prognostic role of body composition parameters in renal cell carcinoma (RCC). (Abstract #4621)

  Emilie Lanoy

• Adherence to oral anticancer drugs (OAD) in patients (pts) with metastatic renal cancer (mRCC): First results of the prospective observational multicenter IPSOC study (Investigating Patient Satisfaction with Oral Anti-cancer Treatment). (Abstract #4622)

  Pascal Wolter

• Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era. (Abstract #4623)

  Che-Kai Tsao

• Molecular characterization of SETD2, a histone methyltransferase, in clear cell renal cell carcinoma (ccRCC). (Abstract #4624)

  Thai Huu Ho

• Updated results on long term overall survival (OS) of the French randomized phase II trial TORAVA in metastatic renal cell carcinoma (mRCC) patients. (Abstract #4625)

  Jacques-Olivier Bay

• Impact of maximum standardized uptake value (SUVmax) evaluated by 18-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) on survival for patients with advanced renal cell carcinoma. (Abstract #4626)

  Noboru Nakaigawa

• Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastases survey. (Abstract #4627)

  Daniele Santini

• Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study. (Abstract #4628)

  Dingwei Ye

• Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients. (Abstract #4629)

  Giuseppe Procopio

• Hypoxia-inducible factor (HIF) 1α and 2α as predictive markers of outcome to VEGFR tyrosine kinase inhibitors (TKI) in renal cell carcinoma (RCC). (Abstract #4630)

  M.I. Saez
• Use of early tumor shrinkage as a response to VEGF inhibitors as a valuable predictor of progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). (Abstract #4631)
  
  Viktor Gruenwald

• Updated safety results from EXIST-2: Everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM). (Abstract #4632)
  
  John Bissler

• Use of miRNA profiling in metastatic renal cell carcinoma to reveal a tumor suppressor effect for mir-215. (Abstract #4633)
  
  George M. Yousef

• Evaluation of selective inhibitors of nuclear export (SINE) CRM1 inhibitors for the treatment of renal cell carcinoma (RCC). (Abstract #4634)
  
  Hiromi Inoue

• Genetic polymorphisms influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents. (Abstract #4635)
  
  Fabio Augusto Barros Schutz

• Efficacy and safety of cancer vaccine with 4-fold gene-modified allogeneic tumor cells: Results of the phase I/II ASET study in patients with advanced renal cell carcinoma. (Abstract #4636)
  
  Steffen Weikert

• Longitudinal serum testosterone levels (T) in long-term testicular cancer survivors (TCSs) in relation to testicular cancer (TC) treatment, aging, and TC diagnosis itself. (Abstract #4637)
  
  Mette Sprauten

• Epidermal growth factor receptor (EGFR) expression and KRAS mutations in penile squamous cell carcinoma: Analysis of potential application of anti-EGFR monoclonal antibodies. (Abstract #4638)
  
  Hongfeng Gou

• Activity of insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic refractory adrenocortical carcinoma. (Abstract #4639)
  
  Aung Naing

• Dynamic sentinel lymph node biopsy in patients with invasive squamous cell carcinoma of the penis: A prospective study of the outcome of 500 inguinal basins assessed in a single institution. (Abstract #4640)
  
  Wayne Lam

• Adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma: Retrospective cohort analysis. (Abstract #4641)
  
  Mouhammed Amir Habra
• Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer. (Abstract #4642)
  
  Karim Fizazi

• Phase I trial of NY-ESO-1/LAGE1 peptide vaccine for metastatic castration resistant prostate cancer (mCRPC). (Abstract #4643)

  Teresa Gray Hayes

• Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial. (Abstract #4644)

  Guru Sonpavde

• Inhibition of 3β-hydroxysteroid dehydrogenase by abiraterone: A rationale for increasing drug exposure in castration-resistant prostate cancer. (Abstract #4645)

  Nima Sharifi

• Polymorphisms in fragile histidine triad gene (FHIT) associated with aggressive prostate cancer and cancer specific mortality. (Abstract #4646)

  Yan Ding

• Guideline-discordant androgen deprivation therapy (ADT) use in localized prostate cancer (CaP) and cost implications: A population-based study. (Abstract #4647)

  Adam Rea Kuykendal

• Overall survival (OS) benefit with sipuleucel-T by baseline PSA: An exploratory analysis from the phase III IMPACT trial. (Abstract #4648)

  Gerald Chodak

• Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue. (Abstract #4649)

  Himisha Beltran

• Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). (Abstract #4650)

  Douglas G. McNeel

• Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT. (Abstract #4651)

  James B. Yu

• Comparing the ability of clinicians and a nomogram model at predicting future 99mTc-bone scan (BS) positivity in patients (pts) with rising prostate-specific antigen (PSA) following radical prostatectomy (RP) for prostate cancer (PCa). (Abstract #4652)

  Michael W. Kattan

• Detecting prostate cancer in BRCA1 and BRCA2 mutation carriers: A role for EN2? (Abstract #4653)

  Emma Killick
Brd. 11E
- A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer (CRPC): A PCCTC trial. (Abstract # 4654)
  
  Emmanuel S. Antonarakis

Brd. 11F
- Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). (Abstract #4655)
  
  William Kevin Kelly

Brd. 11G
- Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4656)
  
  Daniel Peter Petrylak

Brd. 11H
- A national survey of radiation oncologists and urologists on active surveillance for low-risk prostate cancer. (Abstract #4657)
  
  Simon P. Kim

Brd. 12A
- Prostate-specific antigen (PSA) screening in the United States: Patterns of use and PSA outcomes in screened versus unscreened men. (Abstract #4658)
  
  Ian M. Allen

Brd. 12B
- Prevalence of nonmetastatic (M0) prostate cancer (PC) patients on continuous androgen deprivation therapy (ADT) in the United States. (Abstract #4659)
  
  KarynSA Cetin

Brd. 12C
- A first-in-human phase I imaging study using hyperpolarized1c-13 pyruvate (h-Py) in patients (pts) with localized prostate cancer (l-PCa). (Abstract #4660)
  
  Andrea Lynne Harzstark

Brd. 12D
- Correlation of UHRF1 expression in primary prostate cancer patients with adverse prognosis. (Abstract #4661)
  
  Enrico Roggero

Brd. 12E
- Prostate specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. (Abstract #4662)
  
  Anthony E. Mega

Brd. 12F
- Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421). (Abstract #4663)
  
  Amir Goldkorn

Brd. 12G
- Response to ketoconazole (keto) or docetaxel (D) following clinical progression on abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC). (Abstract #4664)
  
  Rahul Raj Aggarwal
• Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC). (Abstract #4665)
  
  Robert B. Montgomery

• Regional variation in survival after metastatic prostate cancer diagnosis. (Abstract #4666)
  
  Darius Lakdawalla

• The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401). (Abstract #4667)
  
  Eric Jay Small

• Incidence-based analysis of lethal prostate cancer in Swedish counties with high versus low incidence of prostate cancer in nationwide, population-based registries. (Abstract #4668)
  
  Pär Stattin

• Association of decreased expression of protein phosphatase 2A subunit PR55γ (PPP2R2C) with an increased risk of metastases and prostate cancer-specific mortality. (Abstract #4669)
  
  Elysia Sophia Spencer

• African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center. (Abstract #4670)
  
  Mitchell Bassett

• Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft. (Abstract #4671)
  
  William Douglas Figg

• Phase II trial of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelial tract who have progressed within less than 12 months after cisplatin-based chemotherapy: A Spanish Oncology Genitourinary Group (SOGUG) study. (Abstract #TPS4672)
  
  Jose Angel Arranz Arija

• Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence. (Abstract #TPS4673)
  
  Dean F. Bajorin

• Vinflunine maintenance therapy versus best supportive care (BSC) after platinum combination in advanced bladder cancer: A phase II, randomized, open-label study (MAJA study)—SOGUG 2011-02. (Abstract #TPS4674)
  
  Sonia Maciá

• Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy. (Abstract #TPS4675^)
  
  Daniel Peter Petrylak
• Phase II trial of gemcitabine, cisplatin, plus ipilimumab as first-line treatment for metastatic urothelial carcinoma. (Abstract #TPS4676)
  *Benjamin Adam Gartrell*

• Phase II study of everolimus (E) in refractory germ cell tumors (GCTs). (Abstract #TPS4677)
  *Michal Mego*

• Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC). (Abstract #TPS4678)
  *Guru Sonpavde*

• An observational study of metastatic renal cell carcinoma patients prior to initiation of initial systemic therapy. (Abstract #TPS4679)
  *Elizabeth R. Plimack*

• A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer (RCC). (Abstract #TPS4680)
  *Eric A. Singer*

• EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901). (Abstract #TPS4681)
  *Ian D. Davis*

• Treatment of refractory metastatic renal cell carcinoma (RCC) with lenvatinib (E7080) and everolimus. (Abstract #TPS4682)
  *Ana M. Molina*

• Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies. (Abstract #TPS4683)
  *Robert John Motzer*

• A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #TPS4684)
  *Laura S. Wood*

• Prospective assessment of circulating endothelial cells (CECs) as early markers of clear cell renal cell carcinoma (CCRCC) progression in first line setting: The Circles study (SOGUG 2011-01). (Abstract #TPS4685)
  *Daniel E. Castellano*

• A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC). (Abstract #TPS4686)
  *Thomas E. Hutson*
Brd. 15F
• Phase I/II study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor entinostat in patients with metastatic renal cell carcinoma. (Abstract #TPS4687)
  Roberto Pili

Brd. 15G
• Phase II study of dovitinib in first line metastatic or non resectable primary adrenocortical carcinoma (ACC). SOGUG study 2011-03. (Abstract #TPS4688)
  Paula Jimenez

Brd. 15H
• CA184-043: A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following a single dose of radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D). (Abstract #TPS4689)
  Charles G. Drake

Brd. 16A
• What is optimal timing of post prostatectomy radiotherapy? Is adjuvant radiotherapy equivalent to early salvage radiotherapy? The “RAVES” phase III randomized clinical trial. (Abstract #TPS4690)
  Maria Pearse

Brd. 16B
• CA184-095: A randomized, double-blind, phase III trial to compare the efficacy of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC). (Abstract #TPS4691)
  Tomasz M. Beer

Brd. 16C
• Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen. (Abstract #TPS4692^)
  Mario A. Eisenberger

Brd. 16D
• A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy. (Abstract #TPS4693)
  Robert Dreicer

Brd. 16E
• A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases. (Abstract #TPS4694)
  Michael J. Morris

Brd. 16F
• A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer. (Abstract #TPS4695)
  Robert B. Montgomery

Brd. 16G
• First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel. (Abstract #TPS4696^)
  Stephane Oudard
• A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC). (Abstract #TPS4697)
  Dana E. Rathkopf

• TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC). (Abstract #TPS4698)
  Edwina S. Baskin-Bey

• Prospect: A randomized, double-blind, phase III efficacy trial of PROSTVAC. (Abstract #TPS4699)
  Olga Bandman

• Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells. (Abstract #TPS4700)
  Susan F. Slovin

• Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer. (Abstract #TPS4701)
  Nishith K. Singh

---

**Session Title:** Gynecologic Cancer  
**Session Type:** General Poster Session  
**Time:** 8:00 AM - 12:00 PM  
**Location:** S Hall A2

• Effect of weekly administration of bevacizumab, gemcitabine, and oxalilplatin in patients with heavily pretreated ovarian cancer. (Abstract #5037)
  Yuji Ikeda

• Phase Ib study of AMG 386 in combination with paclitaxel (P) and carboplatin (C) in high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal, or fallopian tube cancers. (Abstract #5038)
  Antonio Casado

• The combination of intravenous bevacizumab and metronomic oral cyclophosphamide for recurrent platinum-resistant ovarian cancer. (Abstract #5039)
  Emma L. Barber

• ESA use in women with cancer: Consequences of the 2008 FDA clinical alert. (Abstract #5040)
  Kimberly M. Dickinson

• Carboplatin dosing in the treatment of epithelial ovarian cancer (EOC): A Gynecologic Oncology Group (GOG) study. (Abstract #5041)
  Roisin Eilish O'Cearbhaill

• Detection of disseminated tumor cells in bone marrow as an independent prognostic factor in primary ovarian cancer patients. (Abstract #5042)
  Pauline Wimberger
• BRCA1 immunohistochemistry in high-grade serous ovarian cancers (HGS-OC) characterized for BRCA1 germ-line mutations. (Abstract #5043)

  *David Michael Hyman*

• What do 676 primary and recurrent ovarian cancer (OC) patients expect from their doctors and therapy management? Results of a German survey of the northeastern German Society of Gynecological Oncology (NOGGO). (Abstract #5044)

  *Gülten Oskay-Özcelik*

• Correlative study of low serum creatinine and hematological toxicities in Japanese patients with ovarian cancer treated by dose dense TC therapy. (Abstract #5045)

  *Koji Matsumoto*

• Neo-escape: Neoadjuvant extended sequential chemotherapy with adjuvant postoperative treatment for epithelial nonmucinous advanced inoperable peritoneal malignancy. (Abstract #5046)

  *Christopher John Poole*

• Changes of serum glycome in patients suffering from ovarian cancer. (Abstract #5047)

  *Veronique Blanchard*

• NKTR-102 in patients with platinum-resistant ovarian cancer (PROC): Modeling CA125 response and its correlation with tumor response. (Abstract #5048)

  *Yen Lin Chia*

• Longitudinal health-related quality of life assessment: Implications for prognosis in ovarian cancer. (Abstract #5049)

  *Donald Peter Braun*

• Technetium-99m sulfur colloid (TSC) as a phenotypic probe for predicting pharmacokinetics (PK) and palmar-plantar erythrodysesthesia (PPE) toxicity of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC). (Abstract #5050)

  *Hugh Giovinazzo*

• Sexual function, sexual activity, and quality of life in women with ovarian and endometrial cancer. (Abstract #5051)

  *Philipp Harter*

• Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study. (Abstract #5052)

  *Karina Dahl Steffensen*

• Effect of tumor-infiltrating T-lymphocytes on the aggressiveness of epithelial ovarian tumors. (Abstract #5053)

  *Ines Vasconcelos*
• An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer. (Abstract #5054)
  Carol Aghajanian

• The impact of obesity on time to recurrence in ovarian cancer: A retrospective study. (Abstract #5055)
  Karina E Hew

• The impact of interval cytoreduction and age in advanced-stage ovarian cancer: A GOG ancillary study. (Abstract #5056)
  Stuart M. Lichtman

• The impact of interval from surgery to chemotherapy and age in advanced-stage ovarian cancer: A GOG ancillary study. (Abstract #5057)
  Andrew Menzin

• Treatment reality in elderly patients with advanced ovarian cancer: A prospective analysis of the OVCAD consortium. (Abstract #5058)
  Linn Lena Woelber

• NGR-hTNF and doxorubicin in relapsed ovarian cancer (OC). (Abstract #5059)
  Domenica Lorusso

• The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in ovarian cancer patients. (Abstract #5060)
  Jonathan David Boone

• A phase Ib study of the combination of temsirolimus (T) and pegylated liposomal doxorubicin (PLD) in advanced or recurrent breast, endometrial, and ovarian cancer. (Abstract #5061)
  Marye Boers-Sonderen

• Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive epithelial ovarian cancer (EOC). (Abstract #5062^)
  Kenneth H. Kim

• Factors associated with an increased risk of recurrence in women with ovarian granulosa cell tumors. (Abstract #5063)
  Anuj Suri

• Application of an ointment with high radical protection factor as a prevention strategy against PPE. (Abstract #5064)
  Franziska Kluschke

• A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. (Abstract #5065)
  Fiona Simpkins
• Effect of BRCA mutation on prognosis in patients with ovarian cancer: A systematic review and meta-analysis. (Abstract #5066)
  Antonis Valachis

• Management of antiangiogenics’ renovascular safety in ovarian cancer subgroup and intermediate results of the MARS study. (Abstract #5067)
  Vincent Launay-Vacher

• A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study. (Abstract #5068)
  Ana Oaknin

• A novel treatment for ovarian cancer (OC): Anti-Müllerian inhibiting substance type II receptor (MISRII) humanized monoclonal antibody (mAb) 3C23K—Preclinical validation. (Abstract #5069)
  Christine Gaucher

• BRCA1 methylation status in high-grade serous ovarian cancer (HGSOC) patients (pts). (Abstract #5070)
  Ilary Ruscito

• Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data. (Abstract #5071)
  Christina Fotopoulou

• Exposure-response relationship of open-label (OL) AMG 386 monotherapy in patients (pts) with recurrent ovarian cancer. (Abstract #5072)
  Beth Karlan

• Targeting therapy based on preclinical analysis of clinical, molecular, and functional characteristics of individual high-grade serous ovarian cancers. (Abstract #5073)
  Monique Topp

• Proliferation pathway aberration frequencies in BRCA1- and BRCA2-mutated ovarian cancers. (Abstract #5074)
  Deborah A. Zajchowski

• Secondary surgery with intraoperative chemo-hyperthermia in recurrent ovarian adenocarcinoma. (Abstract #5075)
  Jean Marc Bereder

• Inflammatory and nutritional markers as predictors of longer hospital stay and suboptimal residual disease (RD) in ovarian cancer (OVCA). (Abstract #5076)
  Michelle Torres

• Association of SNP genotype in ABCB1 with completion of intraperitoneal chemotherapy in ovarian and primary peritoneal cancer. (Abstract #5077)
  Sergio Enderica Gonzalez
• BRCA mutations and outcome in epithelial ovarian cancer (EOC): Experience in ethnically diverse groups. (Abstract #5078)
  Tamar Safra

• Serum IGFBP4 levels in combination with miliary disease: A candidate predictor of ovarian cancer progression-free survival. (Abstract #5079)
  Samantha Cohen

• A matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single-arm phase II trial versus a consecutive single-center collective of ovarian cancer patients without immunotherapy. (Abstract #5080)
  Klaus Pietzner

• Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC). (Abstract #5081)
  Katrin Marie Sjoquist

• Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer. (Abstract #5082^)
  Ron E. Swensen

• Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer (LACC) and negative positron emission tomography with computerized tomography (PET-CT) in the para-aortic area undergoing laparoscopic para-aortic (PA) lymphadenectomy before chemoradiation therapy. (Abstract #5083)
  Sebastien Gouy

• Prevalence of high-risk human papillomavirus in uterine cervical lesions among older Japanese women. (Abstract #5084)
  Kazuhiro Takehara

• Nuclear Y-box binding protein-1 expression as a prognostic marker and correlation with epidermal growth factor receptor expression in cervical cancer. (Abstract #5085)
  Shin Nishio

• Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix. (Abstract #5086)
  Yutaka Nagai

• How is the current clinical management of endometrial cancer worldwide? An international survey by the North-Eastern German Society of Gynaecological Oncology (NOGGO). (Abstract #5087)
  Robert W. Kraetschell

• The impact of racial disparity on outcomes of patients with early-stage uterine endometrioid carcinoma in an equal-access environment. (Abstract #5088)
  Jared R. Robbins
• Association of smoking with pulmonary recurrences among women with intermediate- to high-risk early-stage endometrial adenocarcinoma. (Abstract #5089)
  
  Lori Elizabeth Weinberg

• External validation of a nomogram predicting overall survival (OS) of women with uterine leiomyosarcoma (ULMS). (Abstract #5090)
  
  Alexia Iasonos

• Pair box (PAX8) protein to predict disease recurrence and its association with outcome in women with endometrial cancer: A retrospective study of 229 patients. (Abstract #5091)
  
  Damanzoopinder Samrao

• Prognostic value of lower uterine segment involvement in high-grade endometrial cancers. (Abstract #5092)
  
  Paola A. Gehrig

• Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. (Abstract #5093)
  
  Roberto Angioli

• The novel biomarker HE4 versus CA125 in detecting endometrial cancer: A case control prospective study. (Abstract #5094)
  
  Francesco Plotti

• Association of adjuvant therapy in early-stage low-risk endometrial cancer with increased mortality: A statewide cancer registry analysis. (Abstract #5095)
  
  Michael R. Milam

• Phase II trial on cisplatin-doxorubicin hydrochloride-paclitaxel (TAP) combination as neoadjuvant chemotherapy (NACT) for locally advanced cervical adenocarcinoma (LACA). (Abstract #5096)
  
  Francesco Raspagliesi

• Analysis of somatic mutation in miRNAs and miRNA regulation-related genes in gynecological cancers: New frameshift mutation of TNRC6A found in endometrial cancer. (Abstract #5097)
  
  Qi Mei

• Clinicopathologic characteristics of endometrial cancer in Lynch syndrome. (Abstract #5098)
  
  Fabrice Lecuru

• Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC). (Abstract #5099)
  
  Maria deLeon

• The effects of age on treatment and outcomes in women with stage IB-IIB cervical cancer. (Abstract #5100)
  
  Dario R. Roque
• Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer. (Abstract #5101)
  
  Israel Zighelboim

Brd. 26C
• Phase II trial of robotic stereotactic radiosurgery (SBRT) in patients with recurrent gynecologic malignancies. (Abstract #5102)
  
  Charles Kunos

Brd. 27A
• Neoadjuvant chemotherapy of docetaxel and carboplatin in patients with stage Ib2 to IIb nonsquamous cervix cancer of the uterus. (Abstract #5103)
  
  Shoji Nagao

Brd. 27B
• A phase II study of dose-dense neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma. (Abstract #5104)
  
  Rajkumar Bikramjit Singh

Brd. 27C
• Prognostic significance of high-risk human papilloma virus (HPV), p16, and p53 status in women with vulvar squamous cell carcinoma (VSCC). (Abstract #5105)
  
  Ghassan Allo

Brd. 28A
• ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer. (Abstract #5106)
  
  Partha Basu

Brd. 28B
• Cervical cancer treatment for operable lesions in a low-resource contemporary setting. (Abstract #5107)
  
  Caroline Dorothy Lynch

Brd. 28C
• Preoperative geriatric assessment (GA) and surgical outcomes in older women with gynecological (gyn) cancer. (Abstract #5108)
  
  Daneng Li

Brd. 29A
• Genome-wide association analysis in host characteristics of progression to high-grade cervical intraepithelial neoplasia for women with human papilloma virus infection and normal cytology. (Abstract #5109)
  
  Chyong-Huey Lai

Brd. 29B
• Validation of the predictive value of modeled HCG residual production “P” in low-risk gestational trophoblastic neoplasia (GTN) patients treated in GOG-174 phase III trial. (Abstract #5110)
  
  Benoit You

Brd. 29C
• Nomogram prediction for overall survival of patients diagnosed with cervical cancer. (Abstract #5111)
  
  Christoph Grimm
• OPSALIN: A phase II placebo-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer treated with carboplatin (Cb) and paclitaxel (P). (Abstract #TPS5112)
  
  Eric Pujade-Lauraine

Brd. 30B
• A study of autologous dendritic cell therapy targeting mucin-1 for treatment of patients with epithelial ovarian cancer in first remission. (Abstract #TPS5113)
  
  Jonathan S. Berek

Brd. 30C
• ACRIN 6695 perfusion CT as prognostic imaging biomarker in ovarian cancer. (Abstract #TPS5114)
  
  Chaan S. Ng

Brd. 31A
• A phase II study of live-attenuated listeria monocytogenes immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265). (Abstract #TPS5115)
  
  Warner King Huh

Brd. 31B
• A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL. (Abstract #TPS5116)
  
  Linda R. Mileshkin

**Session Title: Melanoma/Skin Cancers**

**Session Type:** General Poster Session

**Time:** 8:00 AM - 12:00 PM

**Location:** S Hall A2

Brd. 31C
• Suppression of apoptosis by BRAF inhibitors through off-target inhibition of JNK signaling. (Abstract #8537)
  
  Kenneth Yee Tsai

Brd. 31D
• A prospective study investigating the impact of definitive chemoradiation in locoregionally advanced squamous cell carcinoma of the skin. (Abstract #8538)
  
  Michelle K. Nottage

Brd. 31E
• Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial. (Abstract #8539)
  
  Jean-Francois Baurain

Brd. 31F
• Prognostic value of BRAFV600 mutations in melanoma patients after resection of metastatic lymph nodes. (Abstract #8540)
  
  Philippe Saiag

Brd. 31G
• Characterization of ipilimumab exposure-efficacy/safety response relationships in subjects with previously treated or untreated advanced melanoma. (Abstract #8541)
  
  Yan Feng

Brd. 31H
• Role of cytokine-induced plasticity in melanoma on invasive, therapy-resistant cells that express EMT-related genes and pathways. (Abstract #8542)
  
  Jonathan S. Cebon
• Gene expression profile signature (DecisionDx-Melanoma) to predict visceral metastatic risk in patients with stage I and stage II cutaneous melanoma. (Abstract #8543)
  
  Navneet Dhillon

• Elucidating distinct tumorigenic pathways in nodular versus superficial spreading melanoma. (Abstract #8544)
  
  Joshua Andrew Farhadian

• Serum IL-6 as a prognostic biomarker in patients with stage IIB-III melanoma. (Abstract #8545)
  
  Lise Hoejberg

• BEVATEM: Phase II single-center study of bevacizumab in combination with temozolomide in patients (pts) with first-line metastatic uveal melanoma (MUM): First-step results. (Abstract #8546)
  
  Sophie Piperno-Neumann

• Phase II study of the anti-ganglioside GD3 mouse/human chimeric antibody KW2871 combined with high dose interferon-a2b in patients with metastatic melanoma. (Abstract #8547)
  
  Stergios J. Moschos

• Correlations of molecular alterations in clinical stage III cutaneous melanoma with clinical-pathological features and patients outcome. (Abstract #8548)
  
  Piotr Rutkowski

• Ipilimumab in the treatment of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience. (Abstract #8549)
  
  Shaheer A. Khan

• Early alterations of microRNA expression to predict and modulate melanoma metastasis. (Abstract #8550)
  
  Eva Hernando

• Targeted agents matched with tumor molecular aberrations: Review of 160 patients with advanced melanoma treated in a phase I clinic. (Abstract #8551)
  
  Haby Adel Henary

• Positron emission tomography/computed tomography to improve staging and restaging in Merkel cell carcinoma. (Abstract #8552)
  
  Elena B. Hawryluk

• Effect of the BH3 mimetic ABT-737 on human melanoma cells to apoptosis induced by selective BRAF inhibitors. (Abstract #8553)
  
  Peter Hersey

• Randomized, double-blind, and multicenter phase II trial of rh-endostatin plus dacarbazine versus dacarbazine alone as first-line therapy for the patients with advanced melanoma. (Abstract #8554)
  
  Jun Guo
Brd. 33E
• B-RAF mutation as a pejorative marker in metastatic melanoma. (Abstract #8555)
  Sophie Brissy

Brd. 33F
• Everolimus in combination with paclitaxel and carboplatin in patients with advanced melanoma: A phase II trial of the Sarah Cannon Research Institute (SCRI). (Abstract #8556)
  Ralph J. Hauke

Brd. 33G
• The melanoma risk loci as determinants of melanoma prognosis. (Abstract #8557)
  Justin Rendleman

Brd. 33H
• Patterns of progression in patients (pts) with V600 BRAF-mutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436). (Abstract #8558)
  Mary W. F. Azer

Brd. 34A
• MAGE-A3 expression in patients screened for the DERMA trial: A phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma. (Abstract #8559)
  John F Thompson

Brd. 34B
• Adjuvant sunitinib in high-risk patients with uveal melanoma: A pilot study. (Abstract #8560)
  Matias Emanuel Valsecchi

Brd. 34C
• Association of the activation of the mTOR pathway with prognosis in Chinese melanoma patients. (Abstract #8561)
  Yan Kong

Brd. 34D
• mTOR pathway activation in KIT-mutated melanoma with acquired imatinib resistance. (Abstract #8562)
  Lu Si

Brd. 34E
• Analysis of KIT expression and mutations in sinonasal, genital, and acrolentiginous melanomas. (Abstract #8563)
  Christian R F Bull

Brd. 34F
• High-risk uveal melanoma: A prospective study evaluating the role of magnetic resonance imaging of the liver. (Abstract #8564)
  Ernest Marshall

Brd. 34G
• MicroRNA alterations associated with BRAF status in melanoma. (Abstract #8565)
  Michelle W. Ma

Brd. 34H
• Biomarker for benefit from ipilimumab: Correlation of breadth of humoral tumor-antigen-specific immunity with outcome. (Abstract #8566)
  Sarah Gabrielle Ellis

Brd. 35A
• A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma. (Abstract #8567)
  Lynn Mara Schuchter
Brd. 35B
• Ipilimumab-induced hypophysitis in melanoma patients. (Abstract #8568)
  Typhanie Carré

Brd. 35C
• Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. (Abstract #8569)
  Allison Ackerman

Brd. 35D
• Percutaneous hepatic perfusion (PHP or ChemoSat) with melphalan versus best alternative care (BAC) in patients (pts) with hepatic metastases from melanoma: A post hoc analysis of PHP-randomized versus BAC-to-PHP crossover versus BAC-only pts. (Abstract #8570)
  H. Richard Alexander

Brd. 35E
• Tim-3 expression and function in natural killer cells from advanced melanoma patients. (Abstract #8571)
  Ines Esteves Domingues Pires Da Silva

Brd. 35F
• Use of Cobas 4800 BRAF mutation test for the analysis of BRAF V600 mutations in cytological samples (CS) from metastatic melanoma (MM). (Abstract #8572)
  Salvador Martin-Algarra

Brd. 35G
• Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival. (Abstract #8573)
  Ester Simeone

Brd. 35H
• Development of a melanoma risk prediction model incorporating MC1R genotype and indoor tanning exposure. (Abstract #8574)
  Lauren A Smith

Brd. 36A
• Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg). (Abstract #8575)
  Michael Andrew Postow

Brd. 36B
• Evaluation of chemokine-ligand pathways in pretreatment tumor biopsies as predictive biomarker of response to adoptive therapy in metastatic melanoma patients. (Abstract #8576)
  Davide Bedognetti

Brd. 36C
• Rapid rational drug targeting of Merkel cell polyomavirus (MCV)-positive Merkel cell carcinoma (MCC) using the survivin inhibitor YM155. (Abstract #8577)
  Reety Arora

Brd. 36D
• Diagnosis of melanoma: Importance of comparative analysis and “ugly duckling” sign. (Abstract #8578)
  Jean Jacques Grob

Brd. 36E
• Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update. (Abstract #8579)
  Aleksandar Sekulic
A clinical and translational phase II trial of sequential axitinib and carboplatin/paclitaxel in advanced melanoma. (Abstract #8580)

Alain Patrick Algazi

Assessment of germ-line and somatic alterations in main candidate genes among patients with multiple primary melanoma. (Abstract #8581)

Giuseppe Palmieri

Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma. (Abstract #8582)

Ragini Reiney Kudchadkar

Surgery for patients receiving ipilimumab: Safety profile and immunological insights. (Abstract #8583)

David E. Gyorki

Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma patients with brain metastasis. (Abstract #8584)

Eugene Jon Koay

Metastatic basal cell carcinoma: Differences in survival by site of spread. (Abstract #8585)

Margaret Elizabeth McCusker

Clinical experience with atypical spitzoid tumors in patients younger than age 18: Does fluorescence in situ hybridization predict lymph node metastasis? (Abstract #8586)

Eric J. Stanelle

A phase II, multicenter, open-label study of YM155 plus docetaxel in subjects with stage III (unresectable) or stage IV melanoma. (Abstract #8587)

Joyce Leta Steinberg

KIT, NRAS, BRAF, and PTEN alterations in acral lentiginous melanomas. (Abstract #8588)

Abdlsattar Zebary

TILs in metastatic melanoma tumors: A biomarker for immunotherapy? (Abstract #8589)

Sunandana Chandra

The impact of immune status on clinical outcomes in patients with Merkel cell carcinoma. (Abstract #8590)

Sean Donovan

Vemurafenib (V) in BRAF V600E metastatic melanoma (mM): Analysis of 507 patients (pts) enrolled in the French temporary authorization for use (ATU). (Abstract #8591)

Celeste Lebbe

Molecular profiling and comparative genomic hybridization analysis in human melanoma cell lines and identification of BRAF amplification in a PLX4032 acquired resistance cell line. (Abstract #8592)

Erika Maria Von Euw
• Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-mediate gastrointestinal adverse events. (Abstract #8593)
  
  Vafa Shahabi

• A phase IB study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. (Abstract #8594)
  
  David S. Hong

• Patterns of care in adjuvant systemic therapy of patients with stage III melanoma: A U.S. population-based study. (Abstract #8595)
  
  Boyu Hu

• Detection of BRAF mutations in melanoma: Rate of mutation detection at codon 600 using Sanger sequencing as compared to the cobas 4800 method. (Abstract #8596)
  
  Kevin Z. Qu

• MicroRNAs induced in melanoma treated with combination targeted therapy of temsirolimus and bevacizumab. (Abstract #8597)
  
  Aubrey G Wagenseller

• Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma. (Abstract #8598)
  
  Richard D. Carvajal

• Exhibition of a stem-cell like phenotype with the expression of CD271 in drug-resistant melanoma cells. (Abstract #8599)
  
  Elizabeth Ann Teresa Lieser

• Preoperative peripheral blood lymphocyte/monocyte ratio and survival in patients with resected stage IV melanoma. (Abstract #8600)
  
  Nicole M. Rochet

• Comparison of sun protection modalities in parents and children. (Abstract #8601)
  
  Laurent Mortier

• A phase I/II trial of BKM120 combined with vemurafenib (PLX4032) in BRAFV600E/k mutant advanced melanoma. (Abstract #TPS8602)
  
  Andrea Kantor

• CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma. (Abstract #TPS8603)
  
  Antoni Ribas

• OPTiM: A randomized phase III trial to evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared with subcutaneously (sc) administered GM-CSF for the treatment (tx) of unresectable stage IIIb, IIIc, and IV melanoma. (Abstract #TPS8604)
  
  Howard Kaufman
A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma. (Abstract #TPS8605)

Ernest Marshall

Pilot evaluation of sulforaphane in melanoma patients with multiple atypical nevi: Tissue STAT1 and STAT3 as risk markers. (Abstract #TPS8606)

David Lobur

**Session Title:** Pediatric Oncology  
**Session Type:** General Poster Session  
**Time:** 8:00 AM - 12:00 PM  
**Location:** S Hall A2

Trends in body mass index (BMI) during and after treatment for standard risk (SR) acute lymphoblastic leukemia (ALL): A report from the Children’s Oncology Group (COG). (Abstract #9546)

Susan Joy Lindemulder

Pharmacokinetics (PK) of bendamustine in pediatric patients with relapsed/refractory acute leukemia. (Abstract #9547)

Mona Darwish

Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children’s Oncology Group protocol AALL0631. (Abstract #9548)

Di Sun

Serial assessment of regulatory T cells (Tregs) in pediatric AML: A prospective study. (Abstract #9549)

Anuj Kumar Bansal

Diminished asparaginase turnover due to a germ-line mutation in cathepsin B. (Abstract #9550)

Dunja Maroeslea W.M. Te Loo

Serial assessment of humoral immunity in pediatric AML: A prospective study. (Abstract #9551)

Sameer Bakhshi

Contribution of diet and physical activity to metabolic parameters among survivors of childhood leukemia. (Abstract #9552)

Emily S. Tonorezos

Fever at diagnosis of pediatric acute lymphoblastic leukemia (ALL): Are antibiotics really necessary? (Abstract #9553)

Monica Khurana

Minimal residual disease by flow cytometry at the end of chemotherapy for remission induction in pediatric patients with acute lymphoblastic leukemia: Experience from a center in a low-income country. (Abstract #9554)

Eloy Perez
• YM155 sensitivity in pediatric acute lymphoblastic leukemia. (Abstract #9555)
  
  Bill H. Chang

Brd. 41D
• Diagnostic and treatment challenges of adolescent and young adult oncology patients. (Abstract #9557)
  
  Yanqing Xu

Brd. 41E
• Treatment outcomes of pediatric oncology patients in Zambia. (Abstract #9558)
  
  Jeremy Slone

Brd. 41F
• Results of autologous transplants for children from a tertiary cancer center in India. (Abstract #9559)
  
  Amol Dongre

Brd. 41G
• Evaluation of renal function in children with solid tumors: Comparison between estimation with Schwartz formula and EDTA clearance. (Abstract #9560)
  
  Carole Serrano

Brd. 41H
• Familial risk in pediatric cancer and implications for practice. (Abstract #9561)
  
  Karen Curtin

Brd. 42A
• Mitigating smoothened inhibitor-induced growth plate closure with parathyroid hormone. (Abstract #9562)
  
  Yoav E Timsit

Brd. 42B
• Preclinical study of a Bcl-2 inhibitor in neuroblastoma. (Abstract #9563)
  
  Assila Belounis

Brd. 42C
• Effect of insulin-like growth factor 2 gene expression on pleuropulmonary blastoma and embryonal rhabdomyosarcoma. (Abstract #9564)
  
  Rajkumar Venkatramani

Brd. 42D
• Circulating myeloid-derived suppressor cells in pediatric solid tumor patients. (Abstract #9565)
  
  John M. Goldberg

Brd. 42E
• Intensive alternating 6-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma in children and adolescents: Impact on survival. (Abstract #9566)
  
  Gerges Attia Demian

Brd. 42F
• Diffuse pontine gliomas in children: Do changing strategies change results? (Abstract #9567)
  
  Rejin Kebudi

Brd. 42G
• Demographics, treatment, and outcome of retinoblastoma: A large series with protocol-based management. (Abstract #9568)
  
  Vijay Anand Palkonda Reddy
Brd. 42H
• Long-term outcomes of children with Xp11.2 translocation renal cell carcinoma. (Abstract #9569)
  Hiroshi Asanuma

Brd. 43A
• Preclinical study of a PARP inhibitor in neuroblastoma. (Abstract #9570)
  Anissa Addioui

Brd. 43B
• Substitution of cisplatin for etoposide in 2 of 3 induction cycles of CAV/IE with subsequent irinotecan and vincristine for relapse in adults with Ewing sarcoma (ES) and primitive neuroectodermal tumor (PNET). (Abstract #9571)
  Daniel A. Rushing

Brd. 43C
• High-dose thiotepa: Neurotoxicity and risk factors in children with solid tumors. (Abstract #9572)
  Christophe Maritaz

Brd. 43D
• Do children, adolescents, and young adults with soft tissue sarcoma benefit from early detection of recurrences? Results of a population-based study. (Abstract #9573)
  Tobias M. Dantonello

Brd. 43E
• A multidisciplinary treatment comprising standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for Ewing sarcoma family of tumor (ESFT) in Japan: Results of the first Japan Ewing Sarcoma Study (JESS) 04. (Abstract #9574)
  Atsushi Makimoto

Brd. 43F
• Use of pharmacokinetic modeling to optimize direct inhibition of the "undruggable" target EWS-FLI1 of Ewing sarcoma. (Abstract #9575)
  Jeffrey Toretsky

Brd. 43G
• Pharmacokinetics (PK) of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. (Abstract #9576)
  Ami Vijay Desai

Brd. 43H
• Ifomide/pirarubicin/etoposide/carboplatin (ITEC) as second-line chemotherapy for hepatoblastoma. (Abstract #9577)
  Eiso Hiyama

Brd. 44A
• Cell cycle and apoptosis regulatory protein (CARP)-1 expression in neuroblastoma. (Abstract #9578)
  Santosh S. Hanmod

Brd. 44B
• A phase II trial of docetaxel and irinotecan (DI) in children and young adults with recurrent or refractory Ewing sarcoma family of tumor (ESFT). (Abstract #9579)
  Jong Hyung Yoon

Brd. 44C
• Assessment of peripheral blood T regulatory cells (Tregs) in PNET/Ewing sarcoma: A prospective study. (Abstract #9580)
  Tilak Tvsgk
Brd. 44D
• A phase I trial of MK 2206 in children with refractory solid tumors: A Children’s Oncology Group study. (Abstract #9581)
  Christine L. Phillips

Brd. 44E
• Development of an open-source, flexible framework for interinstitutional data sharing and collaboration. (Abstract #9583)
  Chaim Kirby

Brd. 44F
• Integration of genomic and proteomic data to identify MYCN-regulated genes, proteins, and interaction networks in neuroblastoma cells. (Abstract #9584)
  Kolbrun Kristjansdottir

Brd. 44G
• Proton radiotherapy for rhabomyosarcoma: Preliminary results from a multicenter prospective study. (Abstract #9585)
  Torunn I. Yock

Brd. 44H
• A national survey of general internists’ preferences and knowledge gaps regarding the care of childhood cancer survivors. (Abstract #9586)
  Tara O. Henderson

Brd. 45A
• Patient-perceived facilitators in the transition of survivorship care from the pediatric to adult care setting. (Abstract #9587)
  Karim Thomas Sadak

Brd. 45B
• Insurance retention in adolescent and young adult survivors of malignancies in a vertically integrated health care system. (Abstract #9588)
  Robert Michael Cooper

Brd. 45C
• Psychological study of adolescent and young adult (AYA) cancer patients and their parents throughout and beyond their cancer treatment: A pilot study. (Abstract #9589)
  Helen Hatcher

Brd. 45D
• Trends in survival of childhood solid tumors diagnosed 1985-2008 in the Nordic countries. (Abstract #9590)
  Milada Cvancarova

Brd. 45E
• Bleomycin associated lung toxicity in childhood cancer survivors. (Abstract #9591)
  Alexandra Patricia Zorzi

Brd. 45F
• Effectiveness of using cardiac biomarkers to detect late anthracycline cardiotoxicity in childhood leukemia survivors. (Abstract #9592)
  Beata Mladosievicova

Brd. 45G
• A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to imatinib. (Abstract #TPS9594)
  Michel Zwaan
• Intraperitoneal radioimmunotherapy (RIT) for desmoplastic small round cell tumor (DSRCT). (Abstract #TPS9595)
  
  Shakeel Modak

Br. 46A

• The HERBY study: A phase II open label, randomized, multicenter, comparative study of bevacizumab (Bv)-based therapy in pediatric patients with newly diagnosed supratentorial high-grade glioma (HGG). (Abstract #TPS9596)
  
  Jacques Grill

Br. 46B

• The BERNIE study: A phase II study evaluating addition of bevacizumab (Bv) to chemotherapy in children and adolescents with metastatic rhabdomyosarcoma (mRMS) and non-rhabdomyosarcoma soft tissue sarcoma (mNRSTS). (Abstract #TPS9597^)
  
  Julia C. Chisholm

---

**Session Title:** Sarcoma  
**Session Type:** General Poster Session  
**Time:** 8:00 AM - 12:00 PM  
**Location:** S Hall A2

Br. 46C

• Characteristics of sarcoma patients with long-term response to gemcitabine and paclitaxel. (Abstract #10034)
  
  Daniela Katz

Br. 46D

• Effect of metastasis surgery on overall survival in patients (pts) with advanced soft tissue sarcoma (STS): A subanalysis of the PALSAR trials. (Abstract #10035)
  
  Nuria Kotecki

Br. 46E

• Phase Ib/II study of INNO-206 (EMCH-doxorubicin) in patients with soft tissue sarcoma. (Abstract #10036)
  
  Sant P. Chawla

Br. 46F

• Analysis of a neoadjuvant regimen with a fixed dose of doxorubicin followed by a 10-day course of 27 Gy radiation in the treatment of soft tissue sarcoma (STS) of the extremity/trunk. (Abstract #10037)
  
  John Mathews

Br. 46G

• A retrospective study from the Royal Marsden Hospital (RMH) of patients with malignant perivascular epithelioid cell tumors (PEComa) receiving treatment with sirolimus (SI) or temsirolimus (TSI). (Abstract #10038)
  
  Joanna Vitfell Pedersen

Br. 46H

• Palliative ambulatory 14-day infusional ifosfamide in the outpatient setting for treatment of advanced soft tissue sarcomas (STS): “Old wine in a new bottle.” (Abstract #10039)
  
  Salma Moona Alam

Br. 47A

• Gemcitabine/docetaxel for metastatic or locally advanced soft tissue sarcoma: A retrospective single-center experience. (Abstract #10040)
  
  Gerlinde Egerer
• Pharmacokinetic analyses of vorinostat in patients with metastatic soft tissue sarcoma. (Abstract #10041)
  
  Thomas Schmitt

• Sarcoligo: Impact of local ablative treatment of oligometastatic sarcomas on overall survival. (Abstract #10042)
  
  Juliette Thariat

• Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent nonresectable chondrosarcomas. (Abstract #10043)
  
  Ofer Merimsky

• High-dose ifosfamide (HDI) in metastatic synovial sarcoma: The Institut Gustave Roussy experience. (Abstract #10044)
  
  Arslane Skander Rahal

• Clinical effectiveness of recombinant adenovirus human p53 gene combined with hyperthermia in treatment of advanced soft tissue sarcoma. (Abstract #10045)
  
  Shaowen Xiao

• Rechallenge with ifosfamide-containing regimen as salvage option for patients with metastatic soft tissue sarcomas progressing after multiple pretreatments. (Abstract #10046)
  
  Mathias Hoiczyk

• Association between body weight and efficacy outcomes during trabectedin therapy for recurrent advanced soft tissue sarcoma (STS). (Abstract #10047)
  
  Maurizio D'Incalci

• Differential gene expression in liposarcoma: Insight into pathways for dedifferentiation? (Abstract #10048)
  
  Dale Han

• Interest of tumor to liver ratio 18F-FDG uptake in positron emission tomography for detection of neurofibrosarcoma in neurofibromatosis 1 patients. (Abstract #10049)
  
  Patrick Combemale

• Does combined dose intensification radiotherapy improve disease control in resectable retroperitoneal sarcoma? Long-term results of a phase I/II trial. (Abstract #10050)
  
  Myles JF Smith

• Geriatric high-grade soft tissue sarcoma (G-HG STS): An analysis of 116 patients (pts) evaluating prognostic factors and clinical outcomes stratified by histology. (Abstract #10051)
  
  Richard Hong Hui Quek

• Phase II study of neoadjuvant high-dose ifosfamide with concurrent radiotherapy followed by surgical resection in high-risk soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study. (Abstract #10052)
  
  Xavier Garcia del Muro
• The Italian Rare Cancer Network. (Abstract #10053)

  Roberta Sanfilippo

• Early response to neoadjuvant chemotherapy (NAC) in combination with regional hyperthermia (RHT) to predict long-term survival for adult-type high-risk soft tissue sarcoma (HR-STS): Results of the EORTC-ESHO intergroup phase III study. (Abstract #10054)

  Rolf D. Issels

• Delay in diagnosis and treatment of soft tissue sarcomas (STS): Causes of late intervention and their role in prognosis—A prospective, multidisciplinary group study. (Abstract #10055)

  Alessandro Comandone

• Prospective web-based collection of sarcoma cases diagnosed and treated in France: Experience of the NetSarc network of the French Sarcoma Tumor Boards. (Abstract #10056)

  Francoise Ducimetiere

• Advanced soft-tissue sarcoma in patients over age 75: Patterns of care and survival. (Abstract #10057)

  Delphine Garbay Decoopman

• Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year follow-up study. (Abstract #10058)

  Nicole Jannelle Look Hong

• Risk factors leading to grading changes within 300 low-grade soft tissue sarcomas. (Abstract #10059)

  Tanja Koshrawipour

• Treatment outcomes of primary mediastinal and intrathoracic great vessels sarcoma: Royal Marsden Hospital experience. (Abstract #10060)

  Shir Kiong Lu

• Drug treatment (tx) patterns and survival among patients (pts) with metastatic or recurrent soft tissue sarcoma (m/rSTS) refractory to at least one prior therapy. (Abstract #10061)

  Michael Wagner

• Rechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma following drug holiday: The experience of the French Sarcoma Group (FSG). (Abstract #10062)

  Esma Saada

• Bone metastases in soft tissue sarcoma patients: A survey of natural, prognostic value and treatment. (Abstract #10063)

  Bruno Vincenzi

• Head and neck sarcomas: A comprehensive cancer center experience. (Abstract #10064)

  Mohamadtaki Abdulaziz Tejani
Brd. 50B
• Response to radiation therapy in solitary fibrous tumor/hemangiopericytoma. (Abstract #10065)

  Giacomo Baldi

Brd. 50C
• Preclinical study of trabectedin (TR) and poly(ADP-ribose)polymerase 1 (PARP-1) inhibitor combination in soft tissue sarcoma (STS). (Abstract #10066)

  Ymera Pignochino

Brd. 50D
• Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo. (Abstract #10067)

  Sandrine Marreaud

Brd. 50E
• Whole-body PET/MR in soft tissue sarcoma (STS) patients. (Abstract #10068)

  Stephan Richter

Brd. 50F
• Neoadjuvant chemotherapy for adult soft tissue sarcomas: A phase II trial. (Abstract #10069)

  Samuel Aguiar

Brd. 50G
• Multimodality therapy for pulmonary metastasis in sarcoma patients: Results of a single institution. (Abstract #10070)

  Nasreen A. Vohra

Brd. 50H
• Atypical vascular neoplasms and risk of development of angiosarcoma. (Abstract #10071)

  Vinod Ravi

Brd. 51A
• Effect of anti-β1 integrin antibody on lung seeding of osteosarcoma cells in live mice visualized by single-cell in vivo imaging. (Abstract #10072)

  Hiroaki Kimura

Brd. 51B
• Navigation-assisted surgery for bone and soft tissue tumors with bony extension. (Abstract #10073)

  Makoto Ieguchi

Brd. 51C
• Age as a prognostic factor in osteosarcoma: Survival analysis. (Abstract #10074)

  Maria Pallotta Guadalupe

Brd. 51D
• Efficacy of newly developed platinum complexes against osteosarcoma, bone-targeting platinum, and proteasome inhibitory platinum. (Abstract #10075)

  Kentaro Igarashi

Brd. 51E
• Study of the expression of integrin pathway's proteins as predictive markers of response to neoadjuvant chemotherapy in pretreatment biopsies of patients with high-grade osteosarcoma. (Abstract #10076)

  Elizabeth Laurence Cohen-Jonathan Moyal

Brd. 51F
• Association of the genetic variants in the nucleotide excision repair genes XPA and XPC with cisplatin-induced hearing loss in patients with osteosarcoma. (Abstract #10077)

  Melanie M. Hagleitner
• Primary localized gastrointestinal stromal tumors (GIST) of the duodenum: Final results of a French Sarcoma Group (FSG) retrospective review of 110 patients (pts). (Abstract #10078)
  Thanh Khoa Huynh

• Relationship of CUL4A gene underexpression and prognosis in localized high-risk soft tissue sarcoma (STS) patients of limbs or trunk wall. (Abstract #10079)
  Javier Martin Broto

• Results of pulmonary metastasectomy for osteosarcoma in the pediatric age group. (Abstract #10080)
  Bassam Redwan

• EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma. (Abstract #10081)
  Jeremy Whelan

• Multimodality treatment of pediatric and adult patients with Ewing sarcoma: A single-institution experience. (Abstract #10082)
  David Lorente

• A retrospective safety analysis of adult patients treated with high-dose methotrexate for osteosarcoma in Stockholm, Sweden. (Abstract #10083)
  Daniel Alm

• Activity of MK1775, a selective Wee1 inhibitor, alone or in combination with gemcitabine, in sarcomas. (Abstract #10084)
  Jenny Kreahling

• Pharmacokinetics of escalated dose of imatinib in patients with advanced gastrointestinal stromal tumors. (Abstract #10085)
  Changhoon Yoo

• Early assessment of MCV to predict clinical outcome in patients with advanced gastrointestinal stromal tumors (GIST) receiving imatinib. (Abstract #10086)
  Anastasia Constantinidou

• SDHA and SDHB mutations in KIT/PDGFRA WT gastrointestinal stromal tumors. (Abstract #10087)
  Margherita Nannini

• Diagnosis and initial evaluation of patients with gastrointestinal stromal tumor (GIST): An observational study of 1,226 patients. (Abstract #10088)
  Jonathan C. Trent

• Masitinib in imatinib-naive advanced gastrointestinal stromal tumor (GIST): Five-year follow-up of the French Sarcoma Group phase II trial. (Abstract #10089)
  Axel Le Cesne
• Outcomes of multivisceral resection of gastric gastrointestinal stromal tumors. (Abstract #10090)

  Sabha Ganai

• Single-dimension CT measurements with RECIST 1.1 to evaluate liver metastases in GIST patients on imatinib. (Abstract #10091)

  Gaia Schiavon

• Explored prognostic factors for survival in patients with advanced GIST treated with standard dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group. (Abstract #10092)

  David Pérol

• The role of surgical cytoreduction before imatinib therapy in patients with advanced GIST. (Abstract #10093)

  Hojung An

• Characteristics of gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis. (Abstract #10094)

  Annie Guerin

• Effect of five years of imatinib on cure for patients with advanced GIST: Updated survival results from the prospective randomized phase III BFR14 trial. (Abstract #10095)

  François Bertucci

• Analysis of the quality of reporting surgical procedures in patients undergoing resection for primary gastrointestinal stromal tumors: A reporting tool derived from the EORTC–STBSG 62024 trial. (Abstract #10096)

  Peter Hohenberger

• Genome-wide analysis and characterization of an online sarcoma cohort. (Abstract #10097)

  Kimberly E Barnholt

• Doxorubicin, cisplatin, and ifosfamide (API) as first-line therapy for relapsed or metastatic uterine leiomyosarcoma. (Abstract #10098)

  Julien Hadoux

• A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS). (Abstract #TPS10099)

  William D. Tap

• Randomized phase III, multicenter, open-label study comparing TH-302 in combination with doxorubicin versus doxorubicin alone in subjects with locally advanced unresectable or metastatic soft tissue sarcoma. (Abstract #TPS10100)

  Sant P. Chawla
• Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS).  (Abstract #TPS10101)
  Jean-Yves Blay

Brd. 54G
• Masitinib in comparison to imatinib as first line therapy of patients with advanced gastrointestinal stromal tumor (GIST): A randomized phase III trial. (Abstract #TPS10102)
  Antoine Adenis

Brd. 54H
• Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastastectomy. (Abstract #TPS10103)
  Richard D. Carvajal

Session Title: Promoting Faculty Development for Physician Educators
Session Type: Special Session
  Time: 9:30 AM - 11:30 AM
  Location: S404
  • Welcome and Introductions
    James M. Ford, MD (Chair)
  • Evaluation: What Every Physician Educator Should Know
    John R. Potts, MD
  • Mentoring for Physician Educators
    Mitchell Feldman, MD, MPhil
  • What can ASCO do to support Key Faculty?
    Robert A. Wolff, MD

Session Title: ASCO/Union for International Cancer Control (UICC) Joint Session: The Changing Paradigm of Cancer Care after the United Nations Summit
Session Type: Special Session
  Time: 9:45 AM - 11:00 AM
  Location: E353
  • Opening Remarks
    Eduardo L. Cazap, MD (Co-Chair)
  • Before and after the United Nations Summit: Putting Cancer in the Global Agenda
    John Seffrin, PhD
  • From the Treaty of Paris to the United Nations Summit: Policies, Governments, and Health Care
    David Khayat, MD, PhD
  • Perspectives in Cancer Care and Future Strategies: The Diagonal Approach
    Lawrence N. Shulman, MD
  • Closing Remarks
    Michael Paul Link, MD (Co-Chair)

Session Title: B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology
Session Type: Special Session
  Time: 9:45 AM - 11:00 AM
  Location: S100bc
  • Geriatric Oncology: Realities and Hopes around a Patient’s History
    Matti S. Aapro, MD

Session Title: Drug Shortages: Why Is This Happening and How Can We Treat Our Patients?
**Session Title:** Pediatric Oncology Educational Session in Honor of Dr. James Nachman  
**Session Type:** Education Session  
**Time:** 9:45 AM - 11:00 AM  
**Location:** S504

- Development and Refinement of Augmented Treatment Regimens for High-Risk Acute Lymphoblastic Leukemia  
  *Stephen Hunger, MD (Chair)*  
- Radiotherapy for Hodgkin's Lymphoma: Who Needs It?  
  *Melissa M. Hudson, MD*  
- Anthracycline Use in Rhabdomyosarcoma: Back to the Future?  
  *Carola A. S. Arndt, MD*

**Session Title:** Treatment of the Patient with Castration-Resistant Prostate Cancer - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E451a

- Management of the Patient with Castration-Resistant Prostate Cancer  
  *Tomasz M. Beer, MD*

**Session Title:** Challenging Lung Cancer Cases - Ticketed Session  
**Session Type:** Clinical Problems in Oncology Session  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E451b

- 72 Year Old Male, Former Smoker, with Hx of Stable CAD Sp Surgery and Pathology Showing T2N1M0  
  *Enriqueta Felip, MD*  
- 56 Year Old Female, Former Smoker, Without Co-morbidities, Presenting With A Large RLL Mass, “Bulky” Mediastinal Adenopathy, and Contralateral SCV LN—No Evidence of Distant Metastatic Disease  
  *Jyoti D. Patel, MD (Chair)*  
- 49 Year Old Male, Current Smoker, Presenting With ED SCLC, Only Site of Extra-thoracic Disease Was a Submandibular LN  
  *Karen Kelly, MD*

**Session Title:** Developmental Therapeutics - Experimental Therapeutics  
**Session Type:** Oral Abstract Session  
**Time:** 9:45 AM - 12:45 PM  
**Location:** E Arie Crown Theater

- Co-Chair  
  *Shivaani Kummar, MD*  
- Co-Chair  
  *Thehang H. Luu, MD*
• Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors. (Abstract #3000)
  Jean-Charles Soria
• A first-in-human phase I study of the oral p38 MAPK inhibitor LY2228820 dimesylate in patients with advanced cancer. (Abstract #3001)
  Matthew P. Goetz
• Phase I study of OPB51602, a small molecule inhibitor of STAT3 phosphorylation, in patients with refractory solid malignancies. (Abstract #3002)
  Boon C. Goh
• Discussion
  Jaap Verweij, MD, PhD
• A phase Ib, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. (Abstract #3003)
  Philippe Bedard
• First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors. (Abstract #3004)
  Udai Banerji
• First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors. (Abstract #3005)
  Emiliano Calvo
• Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers. (Abstract #3006^)
  Kent C. Shih
• Discussion
  Ana M. Gonzalez-Angulo, MD, MSc
• First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. (Abstract #3007)
  Ranee Mehra
• A first-in-human phase I study of the oral Notch inhibitor LY900009 in patients with advanced cancer. (Abstract #3008)
  Shubham Pant
• Discussion
  Eunice Lee Kwak, MD, PhD

**Session Title:** Gastrointestinal (Colorectal) Cancer  
**Session Type:** Oral Abstract Session  
**Time:** 9:45 AM - 12:45 PM  
**Location:** E Hall D1

• Co-Chair  
  Georgios Lypas, MD

• Co-Chair  
  Robert S. Warren, MD

• Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial. (Abstract #LBA3500^)
  Christophe Tournigand
• Results of the X-PPECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). (Abstract #LBA3501)
  Johanna C. Bendell
• Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). (Abstract #3502)
  Eric Van Cutsem
• Discussion
  Chris R. Garrett, MD
• Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). (Abstract #CRA3503)
  Dirk Arnold
• Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. (Abstract #3504)
  Lillian L. Siu
• Effects of prior bevacizumab (B) use on outcomes from the VELour study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. (Abstract #3505)
  Carmen Joseph Allegra
• Discussion
  C. D. Blanke, MD
• FOLFOX4 (12 cycles) versus sequential dose-dense FOLFOX7 (6 cycles) followed by FOLFIRI (6 cycles) in patients with initially resectable metastatic colorectal cancer: A GERCOR randomized phase III study (MIROX). (Abstract #3506)
  Mohamed Hebbar
• Impact on survival of primary tumor resection in patients with colorectal cancer and unresectable metastasis: Pooled analysis of individual patients’ data from four randomized trials. (Abstract #3507)
  Matthieu Faron
• EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. (Abstract #3508)
  Bernard Nordlinger
• Discussion
  Michael A. Choti, MD, MBA

**Session Title:** Affordability of Cancer Care: A Global Perspective

**Session Type:** Special Session

**Time:** 11:30 AM - 12:45 PM

**Location:** E353

• Co-Chair
  *Eduardo L. Cazap, MD (Co-Chair)*

• The Increasing Cancer Burden and the Impact of Globalization
  *Peter Boyle, PhD DSc*

• Cost of New Cancer Treatments in Relation to Their Effectiveness
  *Ian Tannock, MD, PhD*

• Current Barriers and Challenges to Cancer Research
  *Tanja Cufer, MD, PhD (Co-Chair)*
• Vision of Global Cancer Research in the Future
  Richard L. Schilsky, MD
• Cancer Care Costs: How to Align Limited Resources for the Greatest Health Benefit
  Thomas J. Smith, MD

**Session Title:** Developing a Targeted Therapy: Issues in the Age of Personalized Therapy  
**Session Type:** Education Session  
**Time:** 11:30 AM - 12:45 PM  
**Location:** E354a

• Oncology Drug Development in the Era of Personalized Medicine  
  Elizabeth Mansfield, PhD
• Go/No-Go Decisions: Lessons Learned from Development of Multiple Targeted Cancer Therapies  
  Gwendolyn A. Fyfe, MD
• Understanding the Hits and Misses: The Clinician's Confusion  
  Karen A. Gelmon, MD (Chair)

**Session Title:** Mucosal Injury in Patients with Cancer: Targeting the Biology  
**Session Type:** Education Session  
**Time:** 11:30 AM - 12:45 PM  
**Location:** S100bc

• Mucosal Complications of Anticancer Therapy  
  Dorothy Mary Kate Keefe, MD, MBBS
• Mucositis: The Molecular Paradigm  
  Stephen T. Sonis, DMSc, DDS
• The Clinical Translation: Practice Guidelines and Emerging Therapies  
  Douglas E. Peterson, DMD, PhD (Chair)

**Session Title:** New Developments in Myeloproliferative Neoplasms  
**Session Type:** Education Session  
**Time:** 11:30 AM - 12:45 PM  
**Location:** E354b

• Insights into Molecular Genetics of Myeloproliferative Neoplasms  
  Jason R. Gotlib, MD
• Classification of the Myeloproliferative Neoplasms and Prognostic Factors  
  Francesco Passamonti, MD
• Therapeutic Advances in MPNs: The Role of New Small-Molecule Inhibitors  
  Srdan Verstovsek, MD, PhD (Chair)

**Session Title:** Treatment of Thyroid Cancers: New Information for Medical Oncologists  
**Session Type:** Education Session  
**Time:** 11:30 AM - 12:45 PM  
**Location:** S406

• Tells Us All About RAI Management Of Tumors, The Known Relevant Pathways In Thyroid Cancer And A Biological Overview In Preparation For Clinical Discussion Of TKIs  
  Michael Xing, MD, PhD
• Perspectives on How to Determine Which Patients to Treat: What Do We Use? TG Levels? Velocity? Bulk Of Dx? Symptoms? What are Non-TKI Treatments and When Should They Be Used?  
  Manisha H. Shah, MD
• No Tkis Are Approved For Thyroid Cancer So What Are The Trial Data?  
  Keith Christopher Bible, MD, PhD
• Whom to Treat with What and When: New Front Line Experiences of Medical Oncologists in Treatment of Thyroid Cancer  
  A. Dimitrios Colevas, MD (Chair)

Session Title: Implementing Geriatric Oncology Research in the Cooperative Groups - Ticketed Session  
Session Type: Meet the Professor Session  
  Time: 11:30 AM - 12:45 PM  
  Location: E451a

• Panel Discussion
  Hyman Bernard Muss, MD

• Panel Discussion
  Harvey Jay Cohen, MD

Session Title: Management of Uncommon Lymphomas: Primary Mediastinal Large Cell, Mantle, and Peripheral T-Cell Lymphoma - Ticketed Session  
Session Type: Clinical Problems in Oncology Session  
  Time: 11:30 AM - 12:45 PM  
  Location: E451b

• Diagnosis and Management of Peripheral T-Cell Lymphoma  
  Steven M. Horwitz, MD (Chair)

• Management of Primary Mediastinal Large Cell Lymphoma: What Are Optimal Inductions Regimens, Role of Radiation, and Therapy of Relapsed Disease  
  Kerry J. Savage, MD, MSc

• Treatment of Mantle Cell Lymphoma  
  Brad S. Kahl, MD

Session Title: Plenary Session Including Science of Oncology Award and Lecture  
Session Type: Plenary Session  
  Time: 1:00 PM - 4:00 PM  
  Location: N Hall B1

• Co-Chair  
  Michael Paul Link, MD

• Co-Chair  
  Ronald Levy, MD

• Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers  
  Rakesh K. Jain, PhD

• Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (Abstract #LBA1)  
  Kimberly L. Blackwell

• Discussion  
  Louis M. Weiner, MD

• Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendrogial tumors (AOD). (Abstract #2)  
  Martin J. Van Den Bent

• Discussant  
  Mark R. Gilbert, MD

• Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. (Abstract #3)  
  Mathias J. Rummel
• Discussant
  
  *Michael E. Williams, MD*

• Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. (Abstract #4)

  *Maha Hussain*

• Discussant

  *William K. Oh, MD*

---

**Session Title:** Post-Plenary Discussion on Prostate Cancer: Abstract #4  
**Session Type:** Special Session  
**Time:** 4:45 PM - 5:15 PM  
**Location:** S100a  

• Speaker  

  *Maha Hussain, MD, FACP*

• Speaker  

  *William K. Oh, MD*

---

**Session Title:** A Dickens Tale of the Treatment of Advanced Breast Cancer: The Past, the Present, and the Future  
**Session Type:** Education Session  
**Time:** 4:45 PM - 6:00 PM  
**Location:** N Hall B1  

• Goals of Care  

  *George W. Sledge, MD (Chair)*

• Lessons Learned from the Past, But Let's Move On  

  *Fatima Cardoso, MD*

• The Present: Current Targets of Interest in Management of Advanced Breast Cancer  

  *Eric P. Winer, MD*

• Looking to the Future: Newer Targeted Therapies in Development  

  *Martine J. Piccart-Gebhart, MD, PhD*

---

**Session Title:** Addressing the Imbalance of Supply and Demand: Integrating Advanced Practice Providers into Survivorship Care  
**Session Type:** Education Session  
**Time:** 4:45 PM - 6:00 PM  
**Location:** S404  

• How a Community Practice Successfully Integrated Non-physician Practitioners into Survivorship Care: Lessons Learned, Pitfalls, and Successes  

  *James Ross Waisman, MD*

• The Imbalance of Supply and Demand in Cancer Survivorship Care: Can Non-physician Providers Help Meet the Unmet Need?  

  *Michael Goldstein, MD (Chair)*

• Assessing the Integration of Physician Assistants into Survivorship Care: Training and Workforce Considerations for the Future  

  *Todd Alan Pickard, PA-C*

• Assessing the Integration of Nurse Practitioners into Survivorship Care: Training and Workforce Considerations for the Future  

  *Kevin C. Oeffinger, MD*

---

**Session Title:** Best Use of Imaging Techniques, Old and New, for Genitourinary Cancers in Clinical Practice  
**Session Type:** Education Session  
**Time:** 4:45 PM - 6:00 PM  
**Location:** E Arie Crown Theater
• Optimal Use of Imaging to Guide Treatment Decisions for Kidney Cancer  
  Walter Michael Stadler, MD (Chair)
• Pitfalls and Practice of Determining Response and Progression in Castration-Resistant Prostate Cancer  
  Charles J. Ryan, MD
• Innovations in Functional Imaging for Genitourinary Cancers  
  Josef J. Fox, MD

**Session Title:** Breast Cancer Chemoprevention: If Not Now, When?  
**Session Type:** Education Session  
**Time:** 4:45 PM - 6:00 PM  
**Location:** E354b
• Evidence for Chemoprevention  
  Nancy E. Davidson, MD
• Evaluating Risk/Benefit Indices for Chemoprevention  
  Worta J. McCaskill-Stevens, MD
• Barriers to Uptake and Translation of Chemoprevention to the Primary Care Setting  
  Abenaa M. Brewster, MD, MHS (Chair)

**Session Title:** Laboratory and Clinical Insights into Resistance to EGFR and ALK Inhibitors in Non-small Cell Lung Cancer  
**Session Type:** Education Session  
**Time:** 4:45 PM - 6:00 PM  
**Location:** E Hall D2
• Laboratory Insights into Resistance to Tyrosine Kinase Inhibitors in Lung Cancer  
  William Pao, MD, PhD
• Clinical Insights into Resistance to EGFR TKIs  
  Lecia V. Sequist, MD, MPH
• Clinical Insights into Resistance to ALK TKIs  
  D. Ross Camidge, MD, PhD (Chair)

**Session Title:** Management of Chronic Lymphocytic Leukemia  
**Session Type:** Education Session  
**Time:** 4:45 PM - 6:00 PM  
**Location:** S406
• Prognosis Factors in CLL: Implications for Management and Therapy  
  Neil E Kay, MD (Chair)
• Novel Agents in Chronic Lymphocytic Leukemia: Purine Analogs, Antibodies, and Beyond  
  Peter Hillmen, PhD
• Transplant in Chronic Lymphocytic Leukemia: To Do It or Not, and If So When and How?  
  John G. Gribben, DSc, MD

**Session Title:** Medical Errors in Cancer Care: Prevention, Disclosure, and Patient and Family Member Responses  
**Session Type:** Education Session  
**Time:** 4:45 PM - 6:00 PM  
**Location:** E353
• Preventing Errors in Oncology: Perspective of a Physician Who Is Also a Patient with Cancer  
  Itzhak Brook, MD, MSc
• Why People Don’t Sue: A Qualitative Study  
  Michael Rowe, PhD
• Oncologists’ Difficulty in Facing and Disclosing Medical Errors in Different Cultures: Practical Suggestions for the Clinic  
  Antonella Surbone, MD, PhD (Chair)
### Session Title: Pontine Gliomas in Children: To Biopsy or Not to Biopsy
#### Session Type: Education Session
- **Time:** 4:45 PM - 6:00 PM
- **Location:** S504
- **Is Biopsy Safe in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma?**
  - **Stephanie Puget, MD, PhD**
- **Identification of Novel Biologic Targets in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma**
  - **Mark W. Kieran, MD, PhD (Chair)**
- **The Ethics of Biopsy in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma**
  - **Nicholas K. Foreman, MD**

### Session Title: Rectal Cancer: New Paradigms beyond Standard Chemotherapy and Radiation
#### Session Type: Education Session
- **Time:** 4:45 PM - 6:00 PM
- **Location:** E Hall D1
- **Changes in Rectal Cancer Surgery and How They Impact What Else Needs to Be Done**
  - **Martin R. Weiser, MD**
- **Understanding Rectal Cancer Risk Groups and Adjusting the Paradigm of One Size Fits All**
  - **David P. Ryan, MD (Chair)**
- **Radiation in Rectal Cancer: What Are the Options? Can It Be Avoided?**
  - **Karyn A. Goodman, MD**

### Session Title: Short- and Long-term Cardiovascular Complications of Cancer Treatment: Overview for the Practicing Oncologist
#### Session Type: Education Session
- **Time:** 4:45 PM - 6:00 PM
- **Location:** S100bc
- **Overview of the Problem**
  - **Gretchen Genevieve Kimmick, MD, MS (Chair)**
- **Short- and Long-term Cardiotoxicity of Anti-cancer Therapy**
  - **Dawn L. Hershman, MD, MS**
- **Recent Advances in Cardiotoxicity of Anti-cancer Therapies**
  - **Marianne Ryberg, MD**
- **Prevention and Management of Cardiovascular Complications of Anti-cancer Therapies: A Cardiologist's Perspective**
  - **Doug Sawyer, MD, PhD**

### Session Title: The Oncologist, the Patient, and the Media
#### Session Type: Education Session
- **Time:** 4:45 PM - 6:00 PM
- **Location:** E354a
- **The Patient: Why Patients Seek Information, How They Use Media, and How We Can Help**
  - **Diane Blum, MSW**
- **From Bedside to Website: How to Help Reporters Gather the Best Medical Information**
  - **Jeremy Manier**
- **Making Time for Internet Information in the Clinical Encounter: A Taxonomy of Patient and Question Types**
  - **Paul R. Helft, MD (Chair)**

### Session Title: Advanced Cervical Cancer: Going with the Evidence - Ticketed Session
#### Session Type: Meet the Professor Session
- **Time:** 4:45 PM - 6:00 PM
Session Title: Chasing Melanoma: Management Issues from Primary Tumor to In Transit Disease - Ticketed Session

Session Type: Clinical Problems in Oncology Session

Time: 4:45 PM - 6:00 PM

Location: E451b

- SLN Mapping in Melanoma
  Vernon K. Sondak, MD (Chair)
- Adjuvant Therapy Of Melanoma In Germany: Interferon And Pegylated Interferon; May Comment On SLN/CLND Topic As Well As Appropriate
  Claus Garbe, MD
- Adjuvant Therapy of Melanoma in the United States
  Leslie Anne Fecher, MD
- The Management of In-Transit Melanoma: Observation versus ILI versus ILP versus Intralesional Therapy—Melanoma Management in Australia
  John F Thompson, MBBS, BSc, MD